Anti-claudin 18A2 antibody and its applications
Antibodies with specific CDR sequences targeting CLD18A2 in gastric, pancreatic, and esophageal cancers address the limitations of current treatments by providing targeted therapy with reduced side effects and improved specificity.
Patent Information
- Application Number
- JP2019521178
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-04-26
- Filing Date
- 2017-07-10
- Publication Date
- 2024-11-21
- Estimated Expiration
- 2037-07-10
AI Technical Summary
Current treatments for gastric cancer, such as type I interferons, suffer from high toxicity and side effects, while antibodies targeting claudin protein 18A2 (CLD18A2) with high specificity are needed for effective cancer treatment and detection, but existing antibodies often bind non-specifically to CLD18A1, limiting their efficacy.
Development of antibodies, including specific CDR sequences (SEQ ID NO:31, 32, 33, 37, 38, 39, 43, 44, 45, 49, 50, 51, 83, 84, 85) and variants, that selectively bind to CLD18A2 with minimal binding to CLD18A1, and their use in chimeric antigen receptors (CARs) for targeted therapy and diagnosis.
The antibodies and CARs provide targeted therapy with reduced side effects by specifically recognizing CLD18A2 in gastric, pancreatic, and esophageal cancers, enhancing treatment efficacy and minimizing non-specific binding.
Smart Images

Figure 0007587921000038 
Figure 0007587921000039 
Figure 0007587921000040
Abstract
Description
[Technical field]
[0001] cross reference This application claims priority to Chinese patent application No. 201610536449.9, filed on July 8, 2016, and PCT international application No. PCT / CN2017 / 082024, filed on April 26, 2017, the entire contents of which are incorporated herein by reference.
[0002] The present invention relates to the field of immunology, and more particularly to an antibody against anti-claudin protein 18A2 and its application. [Background technology]
[0003] Chimeric antigen receptors (CARs) are artificial recombinant receptors that consist of an antigen recognition domain, usually containing a monoclonal antibody, located in the extracellular region, a transmembrane region, and an intracellular activation signal domain for immune response cells.
[0004] Gastric cancer is one of the most common cancers in the world. According to the statistics of the WHO Cancer Control Project, 7 million cancer patients die every year worldwide, of which 700,000 die from gastric cancer. Compared with traditional gastric cancer treatment methods, antibody treatment methods have high specificity and low side effects, so they are expected to be widely used.
[0005] Claudin 18 (CLD18) is an integral membrane protein located in epithelial and endothelial tight junctions with a molecular weight of approximately 27.9 KD. GenBank accession numbers are splice variant 1 (CLD18A1, CLD18.1): NP_057453, NM016369, and splice variant 2 (CLD18A2, CLD18.2): NM_001002026, NP_001002026. Figure 1A shows a comparison of identity between claudin 18A2 (SEQ ID NO: 55) and claudin 18A1 (SEQ ID NO: 57). In normal cells, CLD18A1 is selectively expressed in lung and gastric epithelium, and CLD18A2 is expressed in trace amounts in short-lived cells of normal gastric epithelium, but in tumor cells, CLD18A2 is strongly expressed in all kinds of cancers, for example, 75% of gastric cancer patients have high expression of CLD18A2, 50% of pancreatic cancer patients have high expression of CLD18A2, 30% of esophageal cancer patients have high expression of CLD18A2, and it is also highly expressed in lung cancer, etc. Therefore, finding an antibody that binds to CLD18A2 with higher specificity without binding to CLD18A1 is of great significance for the treatment and detection of cancer.
[0006] Type I interferons include IFNα proteins (identical proteins encoded by a total of 13 human genes, IFNA1 to IFNA13), IFNβ (encoded by a single human and mouse gene, IFNB1), and other interferons that have been less studied. Studies have revealed that type I interferons have anticancer effects on some tumors, which may be due to their immune stimulating function. However, systemic administration of type I interferons may cause immune suppression (Lotrich, FE Major depression during interferon-α treatment: vulnerability and prevention. Dialogues Clin. Neurosci. 11,417-425 (2009)), and are associated with serious adverse events, most commonly fatigue, anorexia, hepatotoxicity, flu-like symptoms and severe depression (Kreutzer, K., Bonnekoh, B., Franke, I., Ulrich, J. & Gollnick, H. Sarcoidosis, myasthenia gravis and anterior ischaemic optic neuropathy:severe side effects of adjuvant interferon-α therapy in malignant melanoma?. J. Dtsch. Dermatol. Ges. 2,689-694(in German)(2004)), which severely limit its application. Summary of the Invention
[0007] The present invention overcomes the problems discussed above and has additional advantages. According to one aspect of the present invention, there is provided an antibody capable of specifically binding to claudin 18A2, characterized in that the antibody comprises a heavy chain CDR selected from the amino acid sequences of SEQ ID NOs: 31, 32, 33, 37, 38, 39, 43, 44, 45, 49, 50, 51, 83, 84, 85 or a variant thereof, and / or a light chain CDR selected from the amino acid sequences of SEQ ID NOs: 34, 35, 36, 40, 41, 42, 46, 47, 48, 52, 53, 54 or a variant thereof.
[0008] In one embodiment, the antibody is an antibody (a) comprising a heavy chain variable region having a CDR1 comprising the amino acid sequence set forth in one of SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:43 or SEQ ID NO:49, a CDR2 comprising the amino acid sequence set forth in one of SEQ ID NO:32, SEQ ID NO:38, SEQ ID NO:44, SEQ ID NO:50, SEQ ID NO:83, SEQ ID NO:84 or SEQ ID NO:85, and a CDR3 comprising the amino acid sequence set forth in one of SEQ ID NO:33, SEQ ID NO:39, SEQ ID NO:45 or SEQ ID NO:51; and SEQ ID NO:53; antibody (c) comprising the heavy chain variable region of antibody (a) and the light chain variable region of antibody (b); and antibody (d) recognizing the same antigenic determinant site as the antigenic determinant site recognized by any one of antibodies (a) to (c).
[0009] In some embodiments, the CDR1, CDR2 and CDR3 regions of the heavy chain variable region of the antibody are SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, or SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, or SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, or SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, or SEQ ID NO:31, SEQ ID NO:83, SEQ ID NO:33, or SEQ ID NO:31, SEQ ID NO:84, SEQ ID NO:33, or SEQ ID NO:49, SEQ ID NO:85, SEQ ID NO:51, and / or the CDR1, CDR2 and CDR3 regions of the light chain variable region of the antibody are SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO: NO:36, or SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, or SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, or SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54.
[0010] In one embodiment, the antibody comprises a heavy chain variable region and a light chain variable region, and has a heavy chain variable region having an amino acid sequence set forth in one of SEQ ID NO:3, or SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:23, SEQ ID NO:27 or SEQ ID NO:29, and a light chain variable region having an amino acid sequence set forth in one of SEQ ID NO:1, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, SEQ ID NO:21 or SEQ ID NO:25. In some embodiments, the antibody is an antibody having a heavy chain variable region set forth in SEQ ID NO:3 and a light chain variable region set forth in SEQ ID NO:1; an antibody having a heavy chain variable region set forth in SEQ ID NO:7 and a light chain variable region set forth in SEQ ID NO:5; an antibody having a heavy chain variable region set forth in SEQ ID NO:11 and a light chain variable region set forth in SEQ ID NO:9; an antibody having a heavy chain variable region set forth in SEQ ID NO:15 and a light chain variable region set forth in SEQ ID NO:13; an antibody having a heavy chain variable region set forth in SEQ ID NO:17 and a light chain variable region set forth in SEQ ID NO:1; an antibody having a heavy chain variable region set forth in SEQ ID NO:19 and a light chain variable region set forth in SEQ ID NO:1; an antibody having a heavy chain variable region set forth in SEQ ID NO:23 and a light chain variable region set forth in SEQ ID NO:21; an antibody having a heavy chain variable region set forth in SEQ ID NO:27 and a light chain variable region set forth in SEQ ID NO:22; an antibody having a heavy chain variable region shown in SEQ ID NO:29 and a light chain variable region shown in SEQ ID NO:25; or an antibody having a heavy chain variable region shown in SEQ ID NO:29 and a light chain variable region shown in SEQ ID NO:25.In one embodiment, the antibody is an antibody having a heavy chain variable region set forth in SEQ ID NO:3 and a light chain variable region set forth in SEQ ID NO:1; an antibody having a heavy chain variable region set forth in SEQ ID NO:17 and a light chain variable region set forth in SEQ ID NO:1; an antibody having a heavy chain variable region set forth in SEQ ID NO:19 and a light chain variable region set forth in SEQ ID NO:1; an antibody having a heavy chain variable region set forth in SEQ ID NO:23 and a light chain variable region set forth in SEQ ID NO:21; an antibody having a heavy chain variable region set forth in SEQ ID NO:27 and a light chain variable region set forth in SEQ ID NO:25; or an antibody having a heavy chain variable region set forth in SEQ ID NO:29 and a light chain variable region set forth in SEQ ID NO:25. In some embodiments, the antibody is a humanized antibody, a chimeric antibody, or a fully humanized antibody, or the antibody is a monoclonal antibody, or the antibody is a single chain antibody or a domain antibody. In some embodiments, the antibody is a humanized antibody selected from an antibody having a heavy chain variable region set forth in SEQ ID NO:27 and a light chain variable region set forth in SEQ ID NO:25, an antibody having a heavy chain variable region set forth in SEQ ID NO:23 and a light chain variable region set forth in SEQ ID NO:21, an antibody having a heavy chain variable region set forth in SEQ ID NO:29 and a light chain variable region set forth in SEQ ID NO:25. In some embodiments, the antibody is selected from an antibody having a heavy chain set forth in SEQ ID NO:63 and a light chain set forth in SEQ ID NO:65, an antibody having a light chain set forth in SEQ ID NO:61 and a heavy chain set forth in SEQ ID NO:59, an antibody having a heavy chain set forth in SEQ ID NO:67 and a light chain set forth in SEQ ID NO:65.
[0011] According to one aspect of the invention, the invention provides a nucleic acid encoding said antibody. According to another aspect of the invention, the invention provides an expression vector comprising said nucleic acid. According to another aspect of the invention, the invention provides a host cell comprising an expression vector according to the invention or having a nucleic acid according to the invention integrated into its genome.
[0012] According to one aspect of the present invention, the present invention provides a use of the antibody according to the present invention for producing a targeted drug, an antibody-drug conjugate, or a multifunctional antibody that specifically targets tumor cells expressing claudin 18A2, or for producing a reagent for diagnosing tumors expressing claudin 18A2, or for producing chimeric antigen receptor-modified immune cells. In one embodiment, the tumors expressing claudin 18A2 include gastric cancer, pancreatic cancer, esophageal cancer, and lung cancer.
[0013] According to one aspect of the present invention, the present invention provides a chimeric antigen receptor comprising an antibody of the present invention, the chimeric antigen receptor comprising the antibody of the present invention, a transmembrane region and an intracellular signal region, which are sequentially linked. In one embodiment, the intracellular signal region is selected from the intracellular signal region sequences of CD3ζ, FcεRIγ, CD27, CD28, CD137, CD134, MyD88, CD40, or a combination thereof, or the transmembrane region comprises the transmembrane region of CD8 or CD28. In one embodiment, the chimeric antigen receptor comprises an antibody, a transmembrane region and an intracellular signal region, which are sequentially linked as follows: an antibody of the present invention, CD8 and CD3ζ; an antibody of the present invention, CD8, CD137 and CD3ζ; or an antibody of the present invention, a transmembrane region of the CD28 molecule, an intracellular signal region of the CD28 molecule and CD3ζ; or an antibody of the present invention, a transmembrane region of the CD28 molecule, an intracellular signal region of the CD28 molecule, CD137 and CD3ζ.
[0014] According to another aspect of the invention, the present invention provides a nucleic acid encoding said chimeric antigen receptor. According to another aspect of the invention, the present invention provides an expression vector comprising a nucleic acid according to the invention. According to another aspect of the invention, the present invention provides a virus comprising a vector according to the invention.
[0015] According to one aspect of the present invention, the present invention provides a use of the chimeric antigen receptor, nucleic acid, expression vector or virus described in the present invention for producing chimeric antigen receptor-modified immune cells that target tumor cells expressing claudin 18A2. In one embodiment, the tumors expressing claudin 18A2 include gastric cancer, pancreatic cancer, esophageal cancer and lung cancer.
[0016] According to one aspect of the present invention, the present invention provides a chimeric antigen receptor-modified immune cell transduced with a nucleic acid, expression vector or virus according to the present invention, or expressing a chimeric antigen receptor according to the present invention on its surface. In one embodiment, the immune cell is a T lymphocyte, a natural killer cell (NK cell) or a NKT lymphocyte. In one embodiment, the immune cell further carries a coding sequence for an exogenous cytokine, or further expresses another chimeric antigen receptor that does not contain CD3ζ but contains the intracellular signaling domain of CD28, the intracellular signaling domain of CD137 or a combination of both, or further expresses a chemokine receptor, preferably the chemokine receptor contains a CCR, or further expresses an siRNA capable of reducing the expression of PD-1 or a protein that blocks PD-L1, or endogenous PD-1 in the cell is knocked out by genome editing technology, or further expresses a safety switch.
[0017] According to one aspect of the present invention, the present invention provides a use of the chimeric antigen receptor-modified immune cells for use in manufacturing a drug for inhibiting a tumor expressing claudin 18A2, preferably the tumor includes gastric cancer, pancreatic cancer, esophageal cancer, and lung cancer.
[0018] According to one aspect of the present invention, the present invention provides a multifunctional immunoconjugate comprising an antibody according to the present invention and a functional molecule selected from a molecule targeting a tumor surface marker, a molecule inhibiting a tumor, a molecule targeting a surface marker of an immune cell, or a detectable marker, bound thereto. In one embodiment, the molecule targeting a surface marker of an immune cell is an antibody that binds to a T cell surface marker, forming a bifunctional antibody involving the antibody according to the present invention and a T cell. According to another aspect of the present invention, the present invention provides a nucleic acid encoding the multifunctional immunoconjugate and a use thereof for producing an antitumor drug. In one embodiment, the nucleic acid encoding the multifunctional immunoconjugate is used to produce a reagent for diagnosing a tumor expressing claudin 18A2. In one embodiment, the nucleic acid encoding the multifunctional immunoconjugate is used to produce a chimeric antigen receptor-modified immune cell. In one embodiment, the immune cell comprises a T lymphocyte, a NK cell, or a NKT lymphocyte.
[0019] According to one aspect of the present invention, the present invention provides a pharmaceutical composition comprising an antibody of the present invention or a nucleic acid encoding said antibody. According to one aspect of the present invention, the present invention provides a pharmaceutical composition comprising an immunoconjugate of the present invention or a nucleic acid encoding said immunoconjugate. According to one aspect of the present invention, the present invention provides a pharmaceutical composition comprising a chimeric antigen receptor of the present invention or a nucleic acid encoding said chimeric antigen receptor. According to one aspect of the present invention, the present invention provides a pharmaceutical composition comprising a chimeric antigen receptor-modified immune cell of the present invention. In an embodiment, said pharmaceutical composition comprises a pharma-ceutically acceptable vector or excipient.
[0020] According to one aspect of the invention, the invention provides a kit comprising a container and a pharmaceutical composition of the invention located in the container, or a container and an antibody of the invention or a nucleic acid encoding said antibody, or an immunoconjugate according to the invention or a nucleic acid encoding said conjugate, or a chimeric antigen receptor according to the invention or a nucleic acid encoding said chimeric antigen receptor, or a chimeric antigen receptor-modified immune cell according to the invention.
[0021] According to one aspect of the present invention, the present invention provides an antigen-binding unit comprising a light chain CDR and a heavy chain CDR, wherein the antigen-binding unit specifically binds to a claudin 18A2 peptide, and wherein the antigen-binding unit does not significantly bind to a claudin 18A1 peptide. According to another aspect of the present invention, the present invention provides an antigen-binding unit comprising a light chain CDR and a heavy chain CDR, wherein the antigen-binding unit specifically binds to a claudin 18A2 peptide, and wherein the antigen-binding unit exhibits less non-specific binding to a claudin 18A1 peptide compared to a reference antigen-binding unit. In some embodiments, the reference antigen-binding unit comprises a light chain amino acid sequence of SEQ ID NO:86 or SEQ ID NO:88 and / or a heavy chain amino acid sequence of SEQ ID NO:87 or SEQ ID NO:89. In some embodiments, the claudin 18A2 peptide comprises the amino acid sequence of SEQ ID NO:55. In some embodiments, the claudin 18A1 peptide comprises the amino acid sequence of SEQ ID NO:57. In some embodiments, the non-specific binding of the antigen-binding unit to the claudin 18A1 peptide is not more than 20% of the specific binding of the antigen-binding unit to the claudin 18A2 peptide. In some embodiments, the binding specificity is measured by flow cytometry analysis. In some embodiments, the binding specificity is measured by FACS. In some embodiments, the binding specificity is measured by ELISA.
[0022] In one embodiment, the EC50 of the antigen-binding unit binding to the claudin 18A2 peptide is less than about 100 nM. In one embodiment, the antigen-binding unit is a monoclonal antibody, a humanized antibody, a chimeric antibody, a multivalent antibody, or a chimeric antigen receptor. In some embodiments, the light chain CDRs comprise LCDR1, LCDR2 and LCDR3, and the heavy chain CDRs comprise HCDR1, HCDR2 and HCDR3, wherein the LCDR1, LCDR2 and LCDR3 have amino acid sequences selected from SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:54, respectively, and wherein the HCDR1, HCDR2 and HCDR3 are selected from SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, In some embodiments, the LCDR1 comprises an amino acid sequence selected from SEQ ID NO:34, SEQ ID NO:40, SEQ ID NO:46 and SEQ ID NO:52. In some embodiments, the LCDR2 comprises an amino acid sequence selected from SEQ ID NO:34, SEQ ID NO:40, SEQ ID NO:46 and SEQ ID NO:52. 35 In one embodiment, the LCDR3 comprises an amino acid sequence selected from SEQ ID NO: 41, SEQ ID NO: 47 and SEQ ID NO: 53. 36In some embodiments, the HCDR1 comprises an amino acid sequence selected from SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:43 and SEQ ID NO:49. In some embodiments, the HCDR2 comprises an amino acid sequence selected from SEQ ID NO:32, SEQ ID NO:38, SEQ ID NO:44, SEQ ID NO:50, SEQ ID NO:83, SEQ ID NO:84 and SEQ ID NO:85. In some embodiments, the HCDR3 comprises an amino acid sequence selected from SEQ ID NO:33, SEQ ID NO:39, SEQ ID NO:45 and SEQ ID NO:51. In some embodiments, the antigen binding unit is an scFv, Fv, Fab or (Fab)2.
[0023] According to one aspect of the invention, the invention provides an antigen binding unit comprising a light chain CDR and a heavy chain CDR, wherein the light chain CDR comprises LCDR1, LCDR2 and LCDR3, and the heavy chain CDR comprises HCDR1, HCDR2 and HCDR3, wherein the LCDR1, LCDR2 and LCDR3 comprise an amino acid sequence having at least 80% identity to an amino acid sequence selected from SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:54, and wherein the HCDR1, HCDR2 and HCDR3 are selected from SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:54. The present invention relates to an amino acid sequence having at least 80% identity to an amino acid sequence selected from SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:83, SEQ ID NO:84 and SEQ ID NO:85.In one embodiment, the light chain CDRs comprise LCDR1, LCDR2 and LCDR3, and the heavy chain CDRs comprise HCDR1, HCDR2 and HCDR3, wherein the LCDR1, LCDR2 and LCDR3 have an amino acid sequence selected from SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:54, respectively, and wherein the HCDR1, HCDR2 and HCDR3 have an amino acid sequence selected from SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID In one embodiment, the LCDR1 comprises an amino acid sequence having at least 80% identity to an amino acid sequence selected from SEQ ID NO:34, SEQ ID NO:40, SEQ ID NO:46 and SEQ ID NO:52. In one embodiment, the LCDR2 comprises an amino acid sequence having at least 80% identity to an amino acid sequence selected from SEQ ID NO:34, SEQ ID NO:40, SEQ ID NO:46 and SEQ ID NO:52. 35 In one embodiment, the LCDR3 comprises an amino acid sequence having at least 80% identity to an amino acid sequence selected from SEQ ID NO:41, SEQ ID NO:47 and SEQ ID NO:53. 36In one embodiment, the HCDR1 comprises an amino acid sequence having at least 80% identity to an amino acid sequence selected from SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:43 and SEQ ID NO:49. In one embodiment, the HCDR2 comprises an amino acid sequence having at least 80% identity to an amino acid sequence selected from SEQ ID NO:32, SEQ ID NO:38, SEQ ID NO:44, SEQ ID NO:50, SEQ ID NO:83, SEQ ID NO:84 and SEQ ID NO:85. In one embodiment, the HCDR3 comprises an amino acid sequence having at least 80% identity to an amino acid sequence selected from SEQ ID NO:33, SEQ ID NO:39, SEQ ID NO:45 and SEQ ID NO:51. In some embodiments, the antigen-binding unit is a monoclonal antibody, a humanized antibody, a chimeric antibody, a multivalent antibody, or a chimeric antigen receptor. In some embodiments, the antigen-binding unit is an scFv, an Fv, an Fab, or an (Fab)2.
[0024] According to one aspect of the invention, the invention provides a chimeric antigen receptor comprising an extracellular antigen binding unit, a transmembrane domain and an intracellular domain, wherein the extracellular antigen binding unit comprises an antigen binding unit of the invention. According to one aspect of the invention, the invention provides a composition comprising the antigen binding unit or chimeric antigen receptor of the invention. In one embodiment, the composition comprises a type I interferon. According to one aspect of the invention, the invention provides an isolated nucleic acid encoding the antigen binding unit or chimeric antigen receptor of the invention and any selected type I interferon. According to one aspect of the invention, the invention provides a vector comprising the nucleic acid of the invention.
[0025] According to one aspect of the present invention, the present invention provides a host cell expressing an antigen binding unit or chimeric antigen receptor of the present invention and an optional type I interferon. According to one aspect of the present invention, the present invention provides a host cell comprising a nucleic acid of an antigen binding unit or chimeric antigen receptor of the present invention and an optional type I interferon. In one embodiment, the host cell is an immune response cell. In one embodiment, the host cell is a T cell, a natural killer cell, a cytotoxic T lymphocyte cell, a natural killer T cell, a DNT cell, and / or a regulatory T cell. In one embodiment, the host cell is an NK92 cell.
[0026] In one embodiment, the host cell is cytotoxic to a cell comprising a claudin 18A2 peptide, wherein the claudin 18A2 peptide comprises the amino acid sequence of SEQ ID NO: 55. In one embodiment, the host cell does not comprise a claudin 18A2 peptide and does not have significant cytotoxicity to a cell comprising a claudin 18A1 peptide, wherein the claudin 18A1 peptide comprises the amino acid sequence of SEQ ID NO: 57, and wherein the claudin 18A2 peptide comprises the amino acid sequence of SEQ ID NO: 55.
[0027] According to one aspect of the invention, the invention provides a method for producing an antigen binding unit or chimeric antigen receptor or composition of the invention comprising culturing a host cell of the invention under suitable conditions and obtaining an expression product of said host cell. According to one aspect of the present invention, the present invention provides a method for inducing cell death comprising a claudin 18A2 peptide, comprising contacting the cell with an antigen binding unit, a chimeric antigen receptor, a composition, or a host cell of the present invention. In some embodiments, the cell is contacted with the antigen binding unit, the chimeric antigen receptor, the composition, or the host cell in vitro. In some embodiments, the cell is contacted with the antigen binding unit, the chimeric antigen receptor, the composition, or the host cell in vivo. In some embodiments, the cell is a cancer cell. In some embodiments, the cell is a solid tumor cell. In some embodiments, the cell is selected from a gastric cancer cell, an esophageal cancer cell, a intestinal cancer cell, a pancreatic cancer cell, a nephroblastoma cell, a lung cancer cell, an ovarian cancer cell, a colon cancer cell, a rectal cancer cell, a liver cancer cell, a head and neck cancer cell, a chronic myeloid leukemia cell, and a gallbladder cancer cell.
[0028] According to one aspect of the invention, the invention provides a method of treating a tumor in an individual in need thereof, the method comprising administering to the individual an effective amount of an antigen binding unit, chimeric antigen receptor, composition or host cell of the invention. In some embodiments, the tumor is a solid tumor. In some embodiments, the tumor is gastric cancer, esophageal cancer, intestinal cancer, pancreatic cancer, nephroblastoma, lung cancer, ovarian cancer, colon cancer, rectal cancer, liver cancer, head and neck cancer, chronic myeloid leukemia or gallbladder cancer. In some embodiments, the method further comprises administering to the individual an additional therapeutic agent. In some embodiments, the additional therapeutic agent is at least one selected from epirubicin, oxaliplatin and 5-fluorouracil. Incorporation by Reference
[0029] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the extent that each publication, patent, or patent application is specifically and individually indicated to be incorporated by reference. [Brief description of the drawings]
[0030] The drawings further illustrate the novel features disclosed herein. The features and advantages disclosed herein can be better understood by reference to the accompanying drawings, but it should be understood that these drawings are merely for the purpose of illustrating specific embodiments for the application of the principles disclosed herein and are not intended to limit the scope of the appended claims. [Figure 1A] FIG. 1A shows a comparison of identity between claudin 18A2 (SEQ ID NO:55) and claudin 18A1 (SEQ ID NO:57). [Figure 1B] FIG. 1B shows the binding of hybridoma supernatants 2B1, 3E12, 4A11 and 8E5 to stably transfected HEK293 cells and the binding of human CLD18A2 and CLD18A1 cells as measured by flow cytometric analysis. [Diagram 2] Shown is a sequence alignment of mouse anti-2B1 (heavy chain variable region SEQ ID NO:3, light chain variable region SEQ ID NO:1), 3E12 (heavy chain variable region SEQ ID NO:7, light chain variable region SEQ ID NO:5), 4A11 (heavy chain variable region SEQ ID NO:11, light chain variable region SEQ ID NO:9), and 8E5 (heavy chain variable region SEQ ID NO:15, light chain variable region SEQ ID NO:13). [Diagram 3] Figure 1 shows the relative binding affinity of mouse anti-2B1, 8E5 ScFv after partial chimerization with human IgG1 Fc to HEK293 cells stably transfected with human CLD18A2. [Figure 4] FIG. 1 shows the relative binding affinities of engineered mouse anti-2B1 antibodies 2B1-N52D, 2B1-S54A after partial chimerization with human IgG1 Fc to HEK293 cells stably transfected with human CLD18A2. [Diagram 5]Figure 1 shows the relative binding affinity of humanized hu2B1-S54A after partial chimerization with human IgG1 Fc to HEK293 cells stably transfected with human CLD18A2. [Figure 6] Humanized hu8E5 was partially chimerized with human IgG1 Fc and the relative binding affinity to HEK293 cells stably transfected with human CLD18A2 is shown. [Figure 7] 1 shows the relative binding affinity of engineered humanized hu8E5-2I to HEK293 cells stably transfected with human CLD18A2. [Figure 8] Figure 8A compares the CDC effects of humanized antibodies hu2B1-S54A, hu8E5-2I, and known chimeric antibody ch-163E12 (see CN103509110A) on HEK293 cells transfected with CLD18A2. Figure 8B compares the CDC results of humanized antibodies hu2B1-S54A, hu8E5-2I, and ch-163E12 on HEK293 cells transfected with CLD18A1. [Figure 9] The ADCC effects of humanized antibodies hu2B1-S54A and hu8E5-2I are compared with those of chimeric antibodies ch-163E12 and ch-175D10 (see CN103509110A). [Figure 10] The killing activities of hu8E5-2I and ch-175D10 in mice are compared. [Figure 11] The in vitro killing activities of hu8E5-28Z, hu8E5-BBZ and hu8E5-28BBZ against different cell lines of T cells are compared. [Figure 12] Compare the in vitro killing activities of hu8E5-28Z, hu8E5-2I-28Z, and hu2B1-hs54A T cells against different cell lines. [Figure 13] A comparison of the in vivo effect of CLDN18A2-CAR T on tumor volume over time in a subcutaneous transplant model of gastric cancer PDX mice (Figure 13A) and a comparison of tumor photographs (Figure 13B). [Figure 14]1 shows the results of a cytokine secretion assay for hu8E5-28Z and hu8E5-2I-28Z. [Figure 15] A comparative graph of the effect of in vivo treatment of CLDN18A2-CART on tumor volume over time in a subcutaneous xenograft model of gastric cancer BGC-823-A2 mice (Figure 15A), a comparative graph of tumor weight (Figure 15B), and a comparative graph of tumor photographs (Figure 15C) are shown. [Figure 16] Shows the tumor infiltration status of CLDN18A2-CAR T. [Figure 17] Figure 17A shows the secretion status of cellular molecules after co-expression of IFN. Figure 17B shows a comparison of the antitumor activity of CAR-T cells with and without IFN in subcutaneously implanted tumors in a gastric cancer PDX model. Figure 17C shows a comparison of the number of viable cells in the peripheral blood of mice 5, 7, and 10 days after the return of CAR-T cells. [Figure 18] Plasmid map for constructing CAR-NK cells. [Figure 19] Measurement of the positive rate of hu8E5-2I-28Z CAR-NK92 and hu8E5-28BBZ CAR-NK92 is shown. [Figure 20] Figure 1 shows the cytotoxicity of hu8E5-2I-28Z CAR-NK92. [Figure 21] Figure 1 shows the cytotoxicity of hu8E5-28BBZ CAR-NK92. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0031] The following detailed description discloses the embodiments disclosed herein in detail. It should be understood that the present specification is not intended to be limited to the specific embodiments disclosed, and can be modified. It will be understood by those skilled in the art that the contents disclosed herein can be modified or changed in various ways, and are all within the scope and spirit of the disclosure. Unless otherwise specified, each embodiment can be arbitrarily combined with any other embodiment.
[0032] Certain embodiments disclosed herein include numerical ranges, and certain aspects of the invention can be described by using ranges. Unless otherwise specified, numerical ranges or methods described in ranges are for the purpose of brevity and convenience, and the scope of the invention should not be understood as a strict limitation on the scope of the invention. Thus, descriptions of methods using ranges should be construed as specifically disclosing all possible subranges and all possible specific numerical points within the ranges, such as if these subranges and numerical points were explicitly written out in the specification. For example, description of a range of 1 to 6 should be considered as specifically disclosing subranges such as 1 to 3, 1 to 4, 1 to 5, 2 to 4, 2 to 6, 3 to 6, etc., and specific numerical points within these ranges, such as 1, 2, 3, 4, 5, and 6. All of the above spirits apply equally, regardless of the broadness of the numerical values. When a range is described, the range includes the endpoints of the range.
[0033] When referring to measurable values such as amounts, temporal durations, and the like, the term "about" includes variations of ±20%, or in some cases ±10%, or in some cases ±5%, or in some cases ±1%, or in some cases ±0.1% of the specified value.
[0034] The terms "activate" and "activation" as used herein may be used interchangeably, and these and other grammatical forms may refer to the process by which cells transition from a quiescent state to an active state. The process may include a response to an antigen, a phenotypic or genetic change in transition and / or a functional active state. For example, the term "activate" may refer to a process by which immune cells are activated in stages. For example, T cells may require at least two signals to be fully activated. The first signal may occur after the TCR is ligated to the antigen-MHC complex, and the second signal may occur by ligation of a costimulatory molecule (see the costimulatory molecules listed in Table 1). Anti-CD3 may simulate the first signal in vitro, and anti-CD28 may simulate the second signal. For example, engineered T cells may be activated by an expressed CAR. Activated or activated immune cells as used herein may refer to a state in which they are sufficiently stimulated to induce detectable cell proliferation, cytokine production, and / or detectable effector function.
[0035] The term "costimulatory molecule" as used herein refers to a homologous binding partner, such as on an immune cell, e.g., a T cell, that mediates a costimulatory response, such as, but not limited to, proliferation, by specifically binding to a costimulatory ligand. A costimulatory molecule is a molecule on a cell surface, other than an antigen receptor or its ligand, that promotes an effective immune response. Costimulatory molecules include, but are not limited to, MHC class I molecules, BTLA and Toll ligand receptors, and OX40, CD27, CD28, CDS, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278), and 4-1BB (CD137). Specific examples of costimulatory molecules include CDS, ICAM-1, GITR, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD160, CD19, CD4, CD8α, CD8β, IL2Rβ, IL2Rγ, IL7Rα, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, and NKG2. D, NKG2C, TNFR2, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG / Cbp, CD19a, and ligands that specifically bind to CD83.
[0036] As used herein, a "costimulatory signal" refers to a signal that, in combination with a first signal, such as TCR / CD3, results in T cell proliferation and / or up-regulation or down-regulation of key molecules.
[0037] The term "antigen-binding unit" as used herein refers to immunoglobulin molecules and immunologically active parts of immune molecules, i.e., molecules that contain an antigen-binding unit site that specifically binds to an antigen ("immune response"). The term "antigen-binding unit" also includes immunoglobulin molecules from various species, including invertebrates and vertebrates. Structurally, the simplest naturally occurring antibody (e.g., IgG) structurally contains four polypeptide chains, two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds. Immunoglobulins represent a large family of molecules that includes several types of molecules, such as IgD, IgG, IgA, IgM, and IgE. The term "immunoglobulin molecule" includes, for example, hybrid or modified antibodies and their fragments. It has been shown that the antigen-binding unit function of an antibody can be performed by fragments of naturally occurring antibodies. Collectively, such fragments are referred to as "antigen-binding units." The term "antigen-binding unit" further includes any molecular structure of a polypeptide chain having a specific shape that corresponds to and recognizes an epitope, where one or more non-covalent interactions stabilize the complex between the molecular structure and the epitope. Specific examples of the antigen-binding unit include a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains, a bivalent fragment (F(ab)2 fragment) containing two Fab fragments linked by disulfide bridges on the hinge region, an Fd fragment consisting of the VH and CH1 domains, an Fv fragment consisting of the VL and VH domains of a single arm of an antibody, a dAb fragment consisting of the VH domain (Ward et al., Nature, 341:544-546, 1989), an isolated complementarity determining region (CDR) or any fusion protein containing such an antigen-binding unit.
[0038] The term "antibody" as used herein includes intact antibodies and any antigen-binding fragment (i.e., "antigen-binding portion") or single chains thereof. A naturally occurring "antibody" refers to a glycoprotein comprising at least two heavy (H) chains and two light (L) chains linked by disulfide bonds. Each heavy chain consists of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The heavy chain constant region consists of three domains, CH1, CH2, and CH3. Each light chain consists of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region consists of one domain, CL. The VH and VL regions can be further subdivided into regions of high variability, called complementarity determining regions (CDRs), separated by more conservative regions, called framework regions (ERs). Each VH and VL consists of three CDRs and four FRs arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant regions of the antibody can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system.
[0039] The term "scFv" refers to a fusion protein comprising at least one antibody fragment comprising a variable region of a light chain and at least one antibody fragment comprising a variable region of a heavy chain, where the light and heavy chain variable regions are contiguous (e.g., via a synthetic linker, such as a short flexible polypeptide linker) and can be expressed as a single polypeptide chain, where the scFv retains the specificity of the intact antibody from which it is derived. Unless specified as used herein, an scFv can have the VL and VH variable regions in any order (e.g., relative to the N-terminus and C-terminus of the polypeptide), and can include VL-linker-VH or VH-linker-VL.
[0040] As used herein, the terms "complementarity determining region" and "CDR" refer to amino acid sequences in the variable region of an antibody that confer antigen specificity and binding affinity. Generally, there are three CDRs in each heavy chain variable region (HCDR1, HCDR2, HCDR3) and three CDRs in each light chain variable region (LCDR1, LCDR2, LCDR3).
[0041] An antigen-binding unit "specifically binds" or is "immunoreactive" with an antigen if it binds the antigen with greater affinity or affinity than it binds to other reference antigens (including polypeptides or other substances).
[0042] The term "humanized" as used herein refers to non-human antibodies, such as rodent or primate, that are hybrid immunoglobulins, immunoglobulin chains or fragments thereof that contain minimal sequence derived from non-human immunoglobulin. In most cases, humanized antibodies are human immunoglobulins (acceptor antibodies) in which residues from the complementarity determining regions (CDRs) of the receptor are replaced with residues from the CDRs of a non-human species (donor antibody) such as mouse, rat, rabbit or primate that has the desired specificity, affinity and properties. In some cases, residues in the Fv framework regions (FRs) of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies can contain residues that are not present in the acceptor antibody but are present in the introduced CDR or framework sequences. These modifications are made to further improve and optimize antibody performance when introduced into the human body and to minimize immunogenicity. In some embodiments, a humanized antibody comprises substantially all, at least one, and usually two, variable domains, all or nearly all of the CDR regions correspond to those of a non-human immunoglobulin, and all or nearly all of the FR regions are from a human immunoglobulin sequence. A humanized antibody can also comprise at least a portion of an immunoglobulin constant region (Fc), usually that of a human immunoglobulin. In some embodiments, a "humanized antibody" can comprise mutations, such as mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo.
[0043] The term "immunoglobulin" or "Ig" as used herein can refer to a class of proteins that can function as antibodies. Antibodies expressed by B cells are sometimes called chimeric antigen receptors or antigen receptors. The five members of this class are IgA, IgG, IgM, IgD, and IgE, where IgG is the most common circulating antibody. It is the most effective immunoglobulin in agglutination, complement fixation, and other antibody responses, and is important in bacterial and viral defense. For example, tumor cell antigens (or "tumor antigens") or pathogen antigens can be recognized by CAR.
[0044] As used herein, the term "isolated" refers to separation from cellular components, or other components, with which the polynucleotide, peptide, polypeptide, protein, antibody, or fragment thereof is normally associated in nature. As will be understood by those skilled in the art, it is not necessary to "isolate" a non-naturally occurring polynucleotide, peptide, polypeptide, protein, antibody, or fragment thereof in order to distinguish it from its natural counterpart. It should be noted that a "concentrated", "isolated" or "diluted" polynucleotide, peptide, polypeptide, protein, antibody, or fragment thereof can be distinguished from its natural counterpart because the concentration or amount of the molecule per volume is greater (concentrated) or less (diluted) than the concentration of its naturally occurring counterpart. The degree of enrichment can be measured on an absolute basis, such as weight per volume of solution, or can be measured relative to other potential interferents present in the source mixture. In some embodiments, the technical solution of the present invention is preferably more enriched. Thus, for example, it is preferably 2-fold enriched, more preferably 10-fold enriched, even more preferably 100-fold enriched, even more preferably 1000-fold enriched. An "isolated" substance can also be provided by methods of artificial construction, such as chemical synthesis or recombinant expression.
[0045] As used herein, "antigen" refers to a substance that is recognized and specifically bound by an antigen-binding unit. Antigens can include peptides, proteins, glycoproteins, polysaccharides, lipids, portions thereof, and combinations thereof. Non-limiting exemplary antigens include tumor antigens or pathogen antigens. "Antigen" can also refer to a molecule that elicits an immune response. Such an immune response can involve the production of antibodies or the activation of specific immunologically-competent cells, or both. Those skilled in the art will appreciate that any macromolecule can be used as an antigen, including any protein or peptide.
[0046] The terms "polypeptide", "peptide" and "protein" are used interchangeably herein and refer to a polymer of amino acids of any length. The polymer may be linear, cyclic or branched, it may contain modified amino acids, particularly conservatively modified amino acids, and it may be interrupted by non-amino acids. The terms also include amino acid polymers modified by sulfation, glycosylation, lipidation, acetylation, phosphorylation, iodination, methylation, oxidation, proteolytic processing, prenylation, racemization, selenoylation, transfer RNA-mediated amino addition (e.g., argination, ubiquitination), or any other manipulation, such as conjugation with a labeled moiety. As used herein, the term "amino acid" refers to natural and / or unnatural or synthetic amino acids, including glycine and the D or L optical isomers, as well as amino acid analogs and peptidomimetics. A polypeptide or amino acid sequence "derived" from a particular protein refers to the source of the polypeptide. The term further includes polypeptides expressed by a particular nucleic acid sequence.
[0047] The term "amino acid modification" (or "modified amino acid") includes amino acid substitution, insertion and / or deletion in a polypeptide sequence. As used herein, "amino acid substitution" or "substitution" refers to the replacement of an amino acid at a particular position in a parent polypeptide sequence with another amino acid. For example, the substitution R94K refers to the substitution of arginine at position 94 with lysine. The same substitution at said same position in a parent polypeptide sequence can be represented as 94K, i.e., the substitution of position 94 with lysine. For purposes of this specification, multiple substitutions are typically separated by a slash. For example, R94K / L78V refers to the double mutant with the substitutions R94K and L78V. As used herein, "amino acid insertion" or "insertion" refers to the addition of an amino acid at a particular position in a parent polypeptide sequence. For example, insertion-94 refers to an insertion at position 94. As used herein, "amino acid deletion" or "deletion" refers to the removal of an amino acid at a particular position in a parent polypeptide sequence. For example, R94 refers to the deletion of arginine at position 94.
[0048] The term "conservative modification" or "conservative sequence modification" as used herein refers to an amino acid modification that does not significantly affect or alter the desired activity or properties of the peptide containing the amino acid sequence. Such conservative modifications include amino acid substitutions, insertions, and deletions. Modifications can be introduced into the antibodies of the invention by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. A conservative amino acid substitution is one in which an amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include those with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid, etc.), and those with non-basic side chains (e.g., arginine, histidine, etc.). acid), uncharged polar side chains (e.g., glycine, asparagine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine, and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, one or more amino acid residues in the CDR or framework regions of the antibodies of the invention can be replaced with another amino acid residue having a similar side chain.
[0049] As used herein, the term "autologous" and other grammatical forms can refer to material from the same origin. For example, a sample (e.g., cells) can be removed, processed, and administered to the same individual (e.g., patient) at a later time. Autologous processes differ from allogeneic processes in which the donor and recipient are different individuals.
[0050] As used herein, "xenotransplantation" and other grammatical forms thereof may include any process in which cells, tissues, or organs are transplanted, implanted, or injected into a recipient, where the recipient and donor are of different species. The cell, organ, and / or tissue transplants described herein may be used for transplantation into humans. Xenotransplants include, but are not limited to, vascularized xenografts, partially vascularized xenografts, non-vascularized xenografts, xenodressings, xenobandages, xenostructures, and the like.
[0051] As used herein, "allograft" and its other grammatical forms (e.g., allogeneic transplantation) can include any process in which cells, tissues, or organs, whose recipient and donor are of the same species but different individuals, are transplanted, implanted, or infused into a recipient. The cell, organ, and / or tissue transplants described herein can be used for allogeneic transplantation into the human body. Allogeneic transplants include, but are not limited to, vascularized allografts, partially vascularized allografts, avascularized allografts, allogeneic dressings, allogeneic bandages, and allogeneic structures.
[0052] As used herein, "autologous transplantation" and other grammatical forms thereof (e.g., autologous transplantation) can include any process in which a cell, tissue, or organ is transplanted, implanted, or injected into a recipient, where the recipient and donor are the same individual. The cell, organ, and / or tissue transplants described herein can be used for autologous transplantation into the human body. Autologous transplants include, but are not limited to, vascularized autotransplants, partially vascularized autotransplants, non-vascularized autotransplants, autologous dressings, autologous bandages, and autologous structures.
[0053] As used herein, the term "chimeric antigen receptor" or "CAR" refers to an engineered molecule that can be expressed by immune cells, including but not limited to T cells or NK cells. CARs are expressed in T cells and can redirect T cells to specifically kill target cells determined by the artificial receptor. The extracellular binding domain of the CAR can be derived from a mouse, humanized antibody, or a fully humanized monoclonal antibody.
[0054] As used herein, "epitope" and other grammatical forms thereof can refer to a portion of an antigen that is recognized by an antibody, a B cell, a T cell, or an artificial cell. For example, an epitope can be a tumor epitope or a pathogen epitope that is recognized by a TCR. Multiple epitopes within an antigen can also be recognized. An epitope can also be mutated.
[0055] "Cell line" or "cell culture" refers to a bacterial, plant, insect, or higher eukaryotic cell grown or maintained in vitro. The progeny of a cell may not be exactly identical (in morphology, genotype, or phenotype) to the parent cell.
[0056] As used herein, the term "engineered" and other grammatical forms thereof can refer to one or more modifications in a nucleic acid, such as a nucleic acid in the genome of an organism. The term "engineered" can refer to the modification, addition, and / or deletion of a gene. An engineered cell can also refer to a cell with an added, deleted, and / or modified gene. An engineered cell can also refer to a cell that expresses a CAR.
[0057] The term "transfection" as used herein refers to the introduction of exogenous nucleic acid into eukaryotic cells. Transfection can be achieved by various means known in the art, including calcium phosphate-DNA co-precipitation, DEAE-dextran mediated transfection, polyamine mediated transfection, electroporation, microinjection, microinjection, liposome fusion, lipofection, protoplast fusion, retroviral infection, and biolistics.
[0058] The term "stable transfection" or "stable transfection" refers to the introduction and integration of exogenous nucleic acid, DNA or RNA, into the genome of a transfected cell. The term "stable transfectant" refers to a cell in which exogenous DNA has been stably integrated into the genomic DNA.
[0059] As used herein, the terms "encoding a nucleic acid molecule," "encoding a DNA sequence," and "encoding DNA" refer to the order or sequence of deoxyribonucleotides along a deoxyribonucleotide chain. The order of these deoxyribonucleotides determines the order of amino acids along a polypeptide (protein) chain. Thus, a nucleic acid sequence codes for an amino acid sequence.
[0060] As used herein, an "individual" refers to any animal, such as a mammal or marsupial. Individuals of the present invention include, but are not limited to, humans, non-human primates (e.g., Macaca mulatta or other types of monkeys), mice, pigs, horses, donkeys, cows, sheep, rats, and any type of poultry.
[0061] As used herein, the term "peripheral blood lymphocytes" (PBLs) and other grammatical forms can refer to lymphocytes that circulate in the blood (e.g., peripheral blood). Peripheral blood lymphocytes can refer to lymphocytes that are not confined to an organ. Peripheral blood lymphocytes can include T cells, NK cells, B cells, or any combination thereof.
[0062] As used herein, the term "immune response cell" (or "immunoreactive cell", "immune effector cell" or "immune cell") may refer to a cell capable of eliciting an immune response. An immune response cell may refer to a cell of the lymphoid or myeloid lineage. Specific examples of immune cells include, but are not limited to, T cells, such as T cells, such as α / β T cells and γ / δ T cells, B cells, natural killer (NK) cells, natural killer T (NKT) cells, mast cells and bone marrow derived phagocytes, their respective precursor cells and their progeny cells.
[0063] As used herein, the term "T cell" and other grammatical forms thereof can refer to a T cell of any origin. For example, the T cell can be a primary T cell, such as an autologous T cell. The T cell can be human or non-human.
[0064] As used herein, the term "T cell activation" or "triggering of T cells" and other grammatical forms thereof can refer to a state in which T cells are sufficiently stimulated to induce detectable cell proliferation, cytokine production, and / or detectable effector function. In some embodiments, "full T cell activation" can be similar to the cytotoxicity of triggered T cells. T cell activation can be measured using various measurements known in the art. The measurements can be ELISA, ELISPOT to measure cytokine secretion, flow cytometry analysis measurements to measure intracellular cytokine expression (CD107), measurements to measure expanded flow cytometry analysis, and cytotoxicity measurements (51Cr release measurements) to determine target cell elimination. The measurements can be compared to artificial cells (CART) using a control (non-artificial cells) to determine the relative activation of the artificial cells compared to the control. It should be noted that the measurements can be compared to artificial cells incubated or contacted with target cells in which the target antigen is not expressed. For example, the comparison can be made with CD19-CART cells incubated with target cells in which CD19 is not expressed.
[0065] As used herein, the term "sequence" and other grammatical forms when applied to a nucleotide sequence can include DNA or RNA and can be single-stranded or double-stranded. Nucleic acid sequences can be mutated. Nucleic acid sequences can have any length, for example, from 2 to 1,000,000 or more nucleotides (or any integer value therebetween or greater), for example, from about 100 to about 10,000 nucleotides or from about 200 to about 500 nucleotides.
[0066] As used herein, the term "effective amount" means an amount that provides a therapeutic or prophylactic benefit.
[0067] As used herein, the term "expression vector" refers to a vector that contains a recombinant polynucleotide that includes an expression control sequence operatively linked to a nucleotide sequence to be expressed. An expression vector contains sufficient cis-acting elements for expression; other elements for expression can be provided by the host cell or an in vitro expression system. Expression vectors include those known in the art, such as, for example, cosmids, plasmids (e.g., nude or contained in liposomes), and viruses (e.g., lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses). The term "lentivirus" as used herein refers to a genus of the Retroviridae family. Retroviruses are unique in that they infect non-dividing cells, and they can deliver large amounts of genetic information to the DNA of host cells, and therefore they are one of the most efficient methods of gene delivery vectors. HIV, SIV, and FIV are all examples of lentiviruses. Lentivirus-derived vectors provide a means to achieve significant levels of gene transfer in vivo.
[0068] The term "operably linked" as used herein refers to a functional link between a control sequence and a heterologous nucleic acid sequence, which linkage results in the expression of the latter. For example, a first nucleic acid sequence is operably linked to a second nucleic acid sequence if the first nucleic acid sequence is functionally related to the second nucleic acid sequence. For example, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Usually, operably linked DNA sequences are contiguous, and when necessary, two protein coding regions are linked in the same reading frame.
[0069] The term "promoter" as used herein is defined as a DNA sequence recognized by the synthetic machinery of the cell or introduced synthetic machinery required to initiate the specific transcription of a polynucleotide sequence.
[0070] The term "vector" as used herein refers to a composition that contains an isolated nucleic acid and is used to deliver the isolated nucleic acid to the inside of a cell. Numerous vectors are known in the art, including, but not limited to, linear polynucleotides, polynucleotides related to ionic or amphiphilic compounds, plasmids, and viruses. Thus, the term "vector" includes autonomously duplicated plasmids or viruses. The term should also be construed to include non-plasmid and non-viral compounds that facilitate the transfer of nucleic acid into a cell, such as polylysine compounds, liposomes, and the like. Examples of viral vectors include, but are not limited to, adenoviral vectors, adeno-associated viral vectors, retroviral vectors, and the like.
[0071] "Host cell" includes an individual cell or cell culture that may be or has been a recipient of a targeting vector. A host cell includes the progeny of a single host cell. Due to natural, accidental, or deliberate mutation, the progeny may not be completely identical to the original parent cell, for example, in morphology or genomic DNA or total DNA complement. A host cell includes a cell that has been transfected in vivo with a vector of the invention. "Host cell" can refer to a prokaryotic cell, eukaryotic cell, or cell line cultured as a single-cell entity, which can be or has been used as a recipient for recombinant vectors or other transfer polynucleotides, including progeny cells that have already been transfected. The term sequence "identity" as used herein refers to the determination of percent identity by comparing two best-matched sequences over a comparison window (e.g., at least 20 positions) in which portions of the polynucleotide or polypeptide sequence have additions or deletions (i.e., gaps), e.g., 20% or fewer (e.g., 5-15%, or 10-12%) gaps, compared to the reference sequence (which does not include additions or deletions) for the two best-matched sequences. The percentage is usually calculated by determining the number of positions at which the same nucleic acid base or amino acid residue occurs in the two sequences to yield the number of correctly matched positions, and dividing the number of correctly matched positions by the total number of positions in the reference sequence (i.e., the window size) and multiplying the result by 100 to yield the percent sequence identity.
[0072] As used herein, the term "disease" or "symptom" or "disease" or the like refers to any alteration or imbalance that impairs or interferes with the normal function of any cell, tissue, or organ. For example, the "disease" includes, but is not limited to, a tumor, a pathogen infection, an autoimmune disease, a T-cell dysfunction disease, or a defective ability to tolerate immune responses (e.g., transplant rejection).
[0073] As used herein, the term "exogenous" refers to a nucleic acid molecule or polypeptide that is not endogenously expressed in a cell or whose expression level is insufficient to achieve a function of overexpression. Thus, "exogenous" includes recombinant nucleic acid molecules or polypeptides expressed in a cell, such as exogenous, heterologous, and overexpressed nucleic acid molecules and polypeptides.
[0074] As used herein, the term "modulation" refers to a positive or negative alteration. Examples of modulation include a 1%, 2%, 10%, 25%, 50%, 75% or 100% change.
[0075] The term "treatment" as used herein refers to clinical intervention that attempts to modify an individual or treat a cell-induced disease, which may be preventative or may intervene in the course of clinical pathology. Therapeutic effects include, but are not limited to, prevention of disease onset or recurrence, alleviation of symptoms, alleviation of any direct or indirect pathological consequences of the disease, prevention of metastasis, delay in progression of the disease, amelioration or alleviation of the pathological condition, alleviation or improvement of prognosis, etc.
[0076] As used herein, the term "constitutive expression" refers to expression under all physiological conditions.
[0077] The term "inducible expression" as used herein means expression under certain conditions, such as when T cells bind to an antigen. Those skilled in the art know how to perform regular "inducible expression".
[0078] In one embodiment, the present specification provides an antigen binding unit comprising a light chain CDR and a heavy chain CDR, wherein the antigen binding unit specifically binds to a claudin 18A2 peptide, and wherein the antigen binding unit does not significantly bind to a claudin 18A1 peptide.
[0079] In one embodiment, the present specification provides an antigen-binding unit comprising a light chain CDR and a heavy chain CDR, wherein the antigen-binding unit specifically binds to a claudin 18A2 peptide, and wherein the antigen-binding unit exhibits less non-specific binding to a claudin 18A1 peptide compared to a reference antigen-binding unit.
[0080] In some embodiments, the antigen binding unit described herein comprises a light chain CDR. The light chain CDR may be a complementarity determining region of the antigen binding unit. The light chain CDR may comprise a contiguous amino acid residue sequence, or a contiguous amino acid residue sequence separated and optionally flanked by non-complementarity determining regions, such as two or more framework regions. In some embodiments, the light chain CDR comprises two or more light chain CDRs, which may be named light chain CDR-1, CDR-2, etc. In some embodiments, the light chain CDR comprises three light chain CDRs, which may be named light chain CDR-1 (LCDR1), light chain CDR-2 (LCDR2), and light chain CDR-3 (LCDR3), respectively. In some embodiments, a set of CDRs present on a common light chain may be collectively referred to as light chain CDRs.
[0081] In some embodiments, the antigen binding unit described herein comprises a heavy chain CDR. The heavy chain CDR may be a complementarity determining region of the antigen binding unit. The heavy chain CDR may comprise a contiguous amino acid residue sequence, or a contiguous amino acid residue sequence that is separated by non-complementarity determining regions, such as two or more framework regions, and may be optionally adjacent. In some embodiments, the heavy chain CDR comprises two or more heavy chain CDRs, which may be named heavy chain CDR-1, CDR-2, etc. In some embodiments, the heavy chain CDR comprises three heavy chain CDRs, which may be named heavy chain CDR-1 (HCDR1), heavy chain CDR-2 (HCDR2), and heavy chain CDR-3 (HCDR3), respectively. In some embodiments, a set of CDRs present on a common heavy chain may be collectively referred to as heavy chain CDRs.
[0082] In some embodiments, the present disclosure provides an antigen binding unit comprising a light chain CDR and a heavy chain CDR, wherein the light chain CDR comprises LCDR1, LCDR2 and LCDR3, and the heavy chain CDR comprises HCDR1, HCDR2 and HCDR3, wherein the amino acid sequences of LCDR1, LCDR2 and LCDR3 have at least 80% identity to an amino acid sequence selected from SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:54, and wherein the amino acid sequences of HCDR1, HCDR2 and HCDR3 have at least 80% identity to an amino acid sequence selected from SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:54. SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:83, SEQ ID NO:84 and SEQ ID NO:85.
[0083] In some embodiments, the present disclosure provides an antigen binding unit comprising a light chain CDR and a heavy chain CDR, wherein the light chain CDR comprises LCDR1, LCDR2 and LCDR3, and the heavy chain CDR comprises HCDR1, HCDR2 and HCDR3, and wherein the amino acid sequences of LCDR1, LCDR2 and LCDR3 are set forth in SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:54. and wherein the amino acid sequences of HCDR1, HCDR2 and HCDR3 have at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identity to an amino acid sequence selected from SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ The amino acid sequence of the present invention has at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% identity to an amino acid sequence selected from SEQ ID NO:83, SEQ ID NO:84 and SEQ ID NO:85.
[0084] In some embodiments, in the antigen binding unit herein, the light chain CDRs comprise LCDR1, LCDR2 and LCDR3, and the heavy chain CDRs comprise HCDR1, HCDR2 and HCDR3, wherein the LCDR1, LCDR2 and LCDR3 have an amino acid sequence selected from SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:54, respectively, and wherein the HCDR1, HCDR2 and HCDR3 have an amino acid sequence selected from SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:54, respectively. Each of the antibodies has an amino acid sequence selected from SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:83, SEQ ID NO:84 and SEQ ID NO:85, respectively.
[0085] In some embodiments, the present disclosure provides an antigen-binding unit, wherein the LCDR1 comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9 identity to an amino acid sequence selected from SEQ ID NO:34, SEQ ID NO:40, SEQ ID NO:46 and SEQ ID NO:52. In some embodiments, the present disclosure provides an antigen-binding unit, wherein the LCDR2 comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9 identity to an amino acid sequence selected from SEQ ID NO:34, SEQ ID NO:40, SEQ ID NO:46 and SEQ ID NO:52. 35, SEQ ID NO:41, SEQ ID NO:47 and SEQ ID NO:53.
[0086] In one embodiment, the present disclosure provides an antigen binding unit, wherein the LCDR3 is selected from the group consisting of SEQ ID NO: 36, SEQ ID NO:42, SEQ ID NO:48 and SEQ ID NO:54. In one embodiment, the present specification provides an antigen binding unit, wherein the HCDR1 comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% identity to an amino acid sequence selected from SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:43, and SEQ ID NO:49. In one embodiment, the present disclosure provides an antigen binding unit, wherein the HCDR2 comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% identity to an amino acid sequence selected from SEQ ID NO:32, SEQ ID NO:38, SEQ ID NO:44, SEQ ID NO:50, SEQ ID NO:83, SEQ ID NO:84, and SEQ ID NO:85. In one embodiment, the present disclosure provides an antigen binding unit, wherein the HCDR3 comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% identity to an amino acid sequence selected from SEQ ID NO:33, SEQ ID NO:39, SEQ ID NO:45, and SEQ ID NO:51.
[0087] In one embodiment, the antigen binding unit of the present invention binds to claudin 18A2 or claudin 18A2 peptide. The term "claudin 18A2" or "claudin 18A2 peptide" (CLD18.2, CLD18A2, CLDN18A2, CLDN18.2, Claudin18.2 or Claudin18A2) as used herein can include any other known derived form, such as a homologue, ortholog, interspecies homologue, codon-optimized form, truncated form, fragmented form, mutant form or post-translationally modified variant of a known claudin 18A2 sequence. In one embodiment, the claudin 18A2 or claudin 18A2 peptide is a peptide having GenBank accession number NP_001002026 (mRNA:NM_001002026). In one embodiment, the claudin 18A2 or claudin 18A2 peptide is a peptide comprising the amino acid sequence of SEQ ID NO:55.
[0088] In some embodiments, the antigen binding unit of the present invention does not significantly bind to the claudin 18A1 peptide. The term "claudin 18A1" or "claudin 18A1 peptide" (CLD18A1, CLD18.1, CLDN18A1, CLDN18.1, Claudin18.1 or Claudin18A1) herein may refer to any other known derived form, such as a homolog, an ortholog, an interspecies homolog, a codon-optimized form, a truncated form, a fragmented form, a mutant form or a post-translationally modified variant of a known claudin 18A1 sequence. In some embodiments, the claudin 18A1 or claudin 18A1 peptide is a peptide having GenBank accession number NP_057453 (mRNA: NM_016369). In some embodiments, the claudin 18A1 or claudin 18A1 peptide is a peptide comprising the amino acid sequence of SEQ ID NO:57.
[0089] The binding specificity can be determined by a complementarity measurement region such as a light chain CDR or a heavy chain CDR. In many cases, the binding specificity is determined by a light chain CDR and a heavy chain CDR. Compared to other reference antigens or reference peptides, a given heavy chain CDR, a light chain CDR, or a combination thereof provides a given binding pocket with greater affinity and / or specificity to claudin 18A2.
[0090] The binding of the antigen-binding unit and the claudin 18A2 peptide can be expressed or expressed by any method known in the art. For example, the binding can be expressed by binding affinity, which can be the strength of the interaction between the antigen-binding unit and the antigen. The binding affinity can be measured by any method known in the art, such as in vitro binding assay. For example, the binding affinity of the antigen-binding unit disclosed herein can be determined when measured in vitro binding assay using cells expressing claudin 18A2. The binding affinity of the tested antigen-binding unit can be expressed as Kd, which is the equilibrium dissociation constant between an antibody and its respective antigen. In some cases, the antigen-binding unit disclosed herein specifically binds to claudin 18A2, and Kd ranges from about 10 μM to about 1 mM. For example, an antigen binding unit can specifically bind to claudin 18A2 with a Kd of less than about 10 μM, 1 μM, 0.1 μM, 10 nM, 1 nM, 0.1 nM, 10 pM, 1 pM, 0.1 pM, 10 fM, 1 fM, or less than 0.1 fM.
[0091] In some embodiments, the antigen-binding unit does not exhibit significant binding to the reference peptide. In some embodiments, the binding level of the antigen-binding unit to the reference peptide is not more than 20% of the binding level of the antigen-binding unit to claudin 18A2. For example, the binding level may be 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less than 1% of the binding level of the antigen-binding unit to claudin 18A2. In some embodiments, the binding level of the antigen-binding unit of the present specification to claudin 18A2 is 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, or more than 10-fold of the binding level of the antigen-binding unit to the reference peptide. In some embodiments, the reference peptide or reference peptide is a claudin 18A1 peptide. In one embodiment, the reference peptide or reference peptide is a peptide comprising the amino acid sequence of SEQ ID NO: 57. In one embodiment, the reference peptide or reference peptide is a peptide of SEQ ID NO: 57.
[0092] In some embodiments, the antigen binding unit herein exhibits less non-specific binding to the reference peptide compared to the reference antigen binding unit. In some embodiments, the antigen binding unit herein exhibits 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% lower than the non-specific binding level of the reference antigen binding unit to the reference peptide. In some embodiments, the non-specific binding level of the antigen binding unit herein to the reference peptide is 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold or more than 10 lower than the binding level of the reference antigen binding unit. In some embodiments, the reference antigen binding unit comprises a light chain amino acid sequence of SEQ ID NO:86 or SEQ ID NO:88 and / or a heavy chain amino acid sequence of SEQ ID NO:87 or SEQ ID NO:89. In some embodiments, the reference antigen binding unit comprises the amino acid sequence of SEQ ID NO:86. In some embodiments, the reference antigen binding unit comprises the amino acid sequence of SEQ ID NO:87. In some embodiments, the reference antigen binding unit comprises the amino acid sequence of SEQ ID NO:88. In some embodiments, the reference antigen binding unit comprises the amino acid sequence of SEQ ID NO:89. In some embodiments, the reference peptide is a claudin 18A1 peptide. In some embodiments, the reference peptide is a peptide comprising the amino acid sequence of SEQ ID NO:57. In some embodiments, the reference peptide is a peptide of SEQ ID NO:57.
[0093] In some embodiments, the antigen binding unit is cytotoxic to a cell comprising a claudin 18A2 peptide, wherein the claudin 18A2 peptide comprises the amino acid sequence of SEQ ID NO: 55. The level of cytotoxicity is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40% or 45% when the ratio of target cells to antigen binding units is 20:1, 10:1, 5:1, 3:1, 2.5:1, 1:1 or 1:3.
[0094] In one embodiment, the antigen binding unit has no significant cytotoxicity against a cell that comprises a claudin 18A1 peptide but not a claudin 18A2 peptide, wherein the claudin 18A1 peptide comprises the amino acid sequence of SEQ ID NO: 57, and the claudin 18A2 peptide comprises the amino acid sequence of SEQ ID NO: 55. In one embodiment, the cytotoxicity level is less than or equal to 10%, 5%, 4%, 3%, 2%, or 1%.
[0095] In one embodiment, the present specification provides an antibody capable of specifically binding to claudin 18A2, the antibody comprising a heavy chain CDR selected from SEQ ID NO:31, 32, 33, 37, 38, 39, 43, 44, 45, 49, 50, 51, 83, 84, 85 or a variant thereof, and / or a light chain CDR selected from SEQ ID NO:34, 35, 36, 40, 41, 42, 46, 47, 48, 52, 53, 54 or a variant thereof.
[0096] In one embodiment, the present disclosure provides an antibody comprising: (a) a heavy chain variable region having a CDR1 comprising the amino acid sequence set forth in one of SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:43, or SEQ ID NO:49, a CDR2 comprising the amino acid sequence set forth in one of SEQ ID NO:32, SEQ ID NO:38, SEQ ID NO:44, SEQ ID NO:50, SEQ ID NO:83, SEQ ID NO:84, or SEQ ID NO:85, and a CDR3 comprising the amino acid sequence set forth in one of SEQ ID NO:33, SEQ ID NO:39, SEQ ID NO:45, or SEQ ID NO:51; and (b) an antibody comprising a heavy chain variable region having a CDR1 comprising the amino acid sequence set forth in one of SEQ ID NO:34, SEQ ID NO:40, SEQ ID NO:46, or SEQ ID NO:52, and a CDR3 comprising the amino acid sequence set forth in one of SEQ ID NO:35, SEQ ID NO:41, SEQ ID NO:52, or SEQ ID NO:52. The present invention provides an antibody selected from the group consisting of: (a) an antibody comprising a light chain variable region having a CDR2 comprising the amino acid sequence shown in any one of SEQ ID NO:47 or SEQ ID NO:53, and a CDR3 comprising the amino acid sequence shown in any one of SEQ ID NO:36, SEQ ID NO:42, SEQ ID NO:48, or SEQ ID NO:54; (c) an antibody comprising the heavy chain variable region of the antibody (a) and the light chain variable region of the antibody (b); and (d) an antibody recognizing the same antigenic determinant site as the antigenic determinant site recognized by any one of the antibodies (a) to (c).In one embodiment, the present disclosure provides an antibody, wherein the CDR1, CDR2 and CDR3 regions of the heavy chain variable region of the antibody are set forth in SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, or SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, or SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, or SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, or SEQ ID NO:31, SEQ ID NO:83, SEQ ID NO:33, or SEQ ID NO:31, SEQ ID NO:84, SEQ ID NO:33, or SEQ ID NO:49, SEQ ID NO:85, SEQ ID NO:51, respectively; and / or the CDR1, CDR2 and CDR3 regions of the light chain variable region of the antibody are set forth in SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, or SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, or SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, NO:35, SEQ ID NO:36, or SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, or SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, or SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54.
[0097] In one embodiment, the amino acid sequences of CDR1, CDR2 and CDR3 of the heavy chain of the antibody of the invention are selected from the group consisting of the amino acid sequences in the following table or variants thereof.
[0098] TIFF0007587921000001.tif139170
[0099] In certain embodiments, the present disclosure provides an antibody in which the amino acid sequences of the light chain CDR1, CDR2 and CDR3 are selected from the group consisting of the amino acid sequences in the table below or variants thereof.
[0100] Table 2 TIFF0007587921000002.tif87170
[0101] In some embodiments, an antibody of the invention comprises a heavy chain variable region selected from amino acid sequence SEQ ID NO:3, 7, 11, 15, 17, 19, 23, 27, 29, or a variant thereof, and / or a light chain variable region selected from amino acid sequence SEQ ID NO:1, 5, 9, 13, 21, 25, or a variant thereof. In some embodiments, the heavy chain variable region is SEQ ID NO:3 or a variant thereof and the light chain variable region is SEQ ID NO:1 or a variant thereof. In some embodiments, the heavy chain variable region is SEQ ID NO:7 or a variant thereof and the light chain variable region is SEQ ID NO:5 or a variant thereof. In some embodiments, the heavy chain variable region is SEQ ID NO:11 or a variant thereof and the light chain variable region is SEQ ID NO:9 or a variant thereof. In some embodiments, the heavy chain variable region is SEQ ID NO:15 or a variant thereof and the light chain variable region is SEQ ID NO:13 or a variant thereof. In a preferred embodiment, the amino acid sequences of the heavy chain CDR1, CDR2 and CDR3 are selected from the table below.
[0102] TIFF0007587921000003.tif69170
[0103] In some embodiments, an antibody of the invention comprises a heavy chain variable region selected from amino acid sequence SEQ ID NO:17, 19, or variants thereof. In some embodiments, the heavy chain variable region is SEQ ID NO:17 or variants thereof and the light chain variable region is SEQ ID NO:1 or variants thereof. In some embodiments, the heavy chain variable region is SEQ ID NO:19 or variants thereof and the light chain variable region is SEQ ID NO:1 or variants thereof.
[0104] In some embodiments, the antibody or functional fragment thereof of the invention comprises a heavy chain variable region selected from the amino acid sequences SEQ ID NO:23, 27, 29 or variants thereof, and / or a light chain variable region selected from the amino acid sequences SEQ ID NO:21, 25 or variants thereof. In some embodiments, the heavy chain variable region is SEQ ID NO:23 or variants thereof and the light chain variable region is SEQ ID NO:21 or variants thereof. In some embodiments, the heavy chain variable region is SEQ ID NO:27 or variants thereof and the light chain variable region is SEQ ID NO:25 or variants thereof. In some embodiments, the heavy chain variable region is SEQ ID NO:29 or variants thereof and the light chain variable region is SEQ ID NO:25 or variants thereof. In certain embodiments, the antigen-binding units or antibodies of the invention are further conjugated to or fused to another functional molecule, and thus the invention also includes the multifunctional immunoconjugates thus formed.
[0105] "Linked" or "fused" may be used interchangeably herein. Such terms refer to the joining of two or more chemical elements or components by any means, including chemical conjugation or recombinant methods. "In-frame fusion" refers to the joining of two or more open reading frames (ORFs) to form a continuous, longer ORF, while maintaining the correct reading frame of the original ORFs. The resulting recombinant fusion protein is thus a single protein containing two or more fragments, which correspond to the polypeptides encoded by the original ORFs (which fragments are not normally joined in the natural state). Thus, although the reading frame is continuous throughout the fusion fragments, the fragments may be physically and spatially separated, for example, by in-frame junction sequences (e.g., "flexons").
[0106] The functional molecule is used, for example, for the diagnosis or treatment of a tumor.
[0107] The term "tumor" as used herein refers to a disease characterized by a pathological proliferation of cells or tissues and subsequent migration or invasion of other tissues or organs. Tumor growth is usually uncontrolled and progressive, and does not induce or inhibit the proliferation of normal cells. Tumors can affect a variety of cells, tissues, or organs, including, but not limited to, those selected from the bladder, bone, brain, breast, cartilage, neuroglial cells, esophagus, fallopian tube, gallbladder, heart, intestine, kidney, liver, lung, lymph nodes, nervous tissue, ovaries, pancreas, prostate, skeletal muscle, skin, spinal cord, spleen, stomach, testes, thymus, thyroid, trachea, urethra, ureter, urethra, uterus, vagina, or tissues or corresponding cells. Tumors include cancers such as sarcomas, carcinomas, or plasmacytomas (malignant tumors of plasma cells). Tumors according to the present invention include leukemias (e.g. acute leukemia, acute lymphocytic leukemia, acute myeloid leukemia, acute myeloid leukemia, acute promyelocytic leukemia, acute granulocytic-monocytic leukemia, acute monocytic leukemia, acute leukemia, chronic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, polycythemia vera), lymphomas (Hodgkin's disease, non-Hodgkin's disease), primary megalocytic proteinemia (primary macroglatulinemia), heavy chain disease, sarcoma and cancer (fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, chordoma, endothelial sarcoma, lymphangiosarcoma, angiosarcoma, lymphangioendothelial sarcoma, synovial vioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, carcinoma, bronchial carcinoma, medullary carcinoma, renal cell carcinoma, The tumor may include, but is not limited to, solid tumors such as alveolar carcinoma, liver cancer, bile duct cancer, choriocarcinoma, seminoma, embryonal carcinoma, nephroblastoma, cervical cancer, uterine cancer, testicular cancer, lung cancer, small cell lung cancer, bladder cancer, epithelial cancer, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pineal tumor, hemangioblastoma, acoustic neuroma, oligodendroglioma, schwannoma, meningioma, melanoma, neuroblastoma, retinoblastoma), esophageal cancer, gallbladder cancer, kidney cancer, and multiple myeloma. Preferably, the "tumor" includes, but is not limited to, pancreatic cancer, liver cancer, lung cancer, gastric cancer, esophageal cancer, squamous cell carcinoma of the head and neck, prostate cancer, colon cancer, breast cancer, lymphoma, gallbladder cancer, kidney cancer, leukemia, multiple myeloma, ovarian cancer, cervical cancer, and glioma.
[0108] The functional molecules include tumor antigens, such as tumor-specific antigens (TSA) or tumor-associated antigens (TAA). TSAs are unique to tumor cells and do not occur in other cells in vivo. TAA-associated antigens are not unique to tumor cells and are expressed in normal cells under conditions that cannot induce immune tolerance to the antigen. Expression of antigens in tumors can occur under conditions that allow the immune system to respond to the antigen. When the immune system is immature and unable to respond, TAAs may be antigens expressed on normal cells during fetal development, or they may be antigens that are normally present at very low levels in normal cells, but are expressed at higher levels in tumor cells.
[0109] Non-limiting examples of TSA or TAA antigens include differentiation antigens such as MART-1 / MelanA (MART-I), gp100 (Pmel17), tyrosinase, TRP-1, TRP-2, tumor-specific multiple antigens such as MAGE-1, MAGE-3, BAGE, GAGE-1, GAGE-2, P15, overexpressed embryonic antigens such as CEA, overexpressed oncogenes and mutated tumor suppressor genes such as p53, Ras, HER-2 / neu, unique tumor antigens resulting from chromosomal translocations such as BCR-ABL, E2A-PRL, H4-RET, IGH-IGK, and MYL-RAR, and viral antigens such as Epstein-Barr virus antigen EBVA, human papillomavirus (HPV) antigens E6 and E7. Other large protein-based antigens include TSP-180, MAGE-4, MAGE-5, MAGE-6, RAGE, NY-ESO, p185erbB2, p180erbB-3, c-met, nm-23H1, PSA, TAG-72, CA 19-9, CA 72-4, CAM 17.1, NuMa, K-ras, β-catenin, CDK4, Mum-1, p 15, p 16, 43-9F, 5T4, 791Tgp72, alpha fetal protein, beta-HCG, BCA225, BTAA, CA 125, CA 15-3\CA 27.29\BCAA, CA 195, CA These include 242, CA-50, CAM43, CD68\P1, CO-029, FGF-5, G250, Ga733\EpCAM, HTgp-175, M344, MA-50, MG7-Ag, MOV18, NB / 70K, NY-CO-1, RCAS1, SDCCAG16, TA-90\Mac-2 binding protein\cyclophilin C-related protein, TAAL6, TAG72, TLP and TPS.
[0110] In one embodiment, the "tumor antigen" is selected from the group consisting of prostate-specific membrane antigen (PSMA), carcinoembryonic antigen (CEA), IL13Ralpha, HER-2, CD19, NY-ESO-1, HIV-1 Gag, Lewis Y, MART-1, gp100, tyrosinase, WT-I, hTERT, mesothelin, EGFR, EGFRvIII, phosphatidylinositol 3, EphA2, HER3, EpCAM, MUC1, MUC16, folate receptor, CLDN6, CD30, CD138, ASGPR1, CDH16, GD2, 5T4, 8H9, αvβ6 integrin, B-cell maturation antigen (BCMA), B7-H3, B7-H6, CAIX, CA9, CD20, CD22, kappa light chain, and the like. chain), CD33, CD38, CD44, CD44v6, CD44v7 / 8, CD70, CD123, CD171, CSPG4, EGP2, EGP40, ERBB3, ERBB4, ErbB3 / 4, FAP, FAR, FBP, embryonic AchR, GD2, GD3, HLA-AI MAGE A1, MAGE3, HLA-A2, IL11Ra, KDR, Lambda, MCSP, NCAM, NKG2D ligand, PRAME, PSCA, PSC1, ROR1, Sp17, SURVIVIN, TAG72, TEM1, TEM8, VEGRR2, HMW-MAA, VEGF receptor, and / or oncofetal variants of fibronectin, tenascin, or tumor necrotic regions.
[0111] In one embodiment, the functional molecule is an interferon. In one embodiment, the interferon is a type I interferon.
[0112] The term "type I interferon" as used herein includes IFNα, IFNβ, and IFN-ε, IFN-κ, and IFN-ω, etc. All type I interferons bind to a specific cell surface receptor (i.e., the so-called IFN-α / β receptor), which is entirely composed of two chains, IFNAR1 and IFNAR2. In one embodiment, the term "type I interferon" as used herein is IFNα or IFNβ. In one embodiment, the term "type I interferon" as used herein is IFNβ. In one embodiment, the type I interferon as used herein includes human, murine, or synthetic type I interferon. In one embodiment, the term "interferon α" as used herein may be a polypeptide having a sequence set forth in NCBI aaa52724.1 or aaa52716.1 or aaa52725.1, or a polypeptide whose sequence has at least 85% identity to these sequences. In some embodiments, the term "interferon beta" (INF-β) as used herein may refer to a protein having at least 85% identity to NCBI aac41702.1 or np_002167.1 or aah96152.1p41273 or NP 001552, or a tumor necrosis factor (TNF) ligand functional fragment thereof. In some embodiments, the interferon beta is human interferon beta. In some embodiments, the interferon beta has the amino acid sequence of SEQ ID NO:92.
[0113] In one embodiment, the type I interferon may be naturally occurring, for example, it may be isolated or purified from a mammal, or it may be artificially produced, for example, the recombinant element or type I interferon is produced according to conventional recombinant genetic engineering techniques.Preferably, the recombinant element or type I interferon can be used in the present invention.
[0114] The present invention also includes amino acid sequences formed by substitution, deletion or addition of one or more amino acid residues based on the above type I interferon polypeptide sequence. The appropriate substitution of amino acids is a technique known in the art, and said technique can be easily performed, ensuring that the biological activity of the resulting molecule is not altered. Based on these techniques, those skilled in the art will generally recognize that the modification of a single amino acid in a non-essential region of a polypeptide does not fundamentally change the biological activity.
[0115] Based on the type I interferon polypeptide sequence, modified or improved polypeptides can also be used in the present invention, for example, to improve the half-life, efficacy, metabolism, and / or potency of the polypeptide. In other words, any alteration that does not affect the biological activity of the polypeptide can be used in the present invention.
[0116] Any biologically active fragment of the type I interferon polypeptide can be applied to the present invention. Here, the biologically active fragment means that the polypeptide, which is a part of the full-length polypeptide, can still retain all or part of the function of the full-length polypeptide. Usually, the biologically active fragment retains at least 50% of the activity of the full-length polypeptide. Under more preferred conditions, the active fragment can retain 60%, 70%, 80%, 90%, 95%, 99%, or 100% of the activity of the full-length polypeptide.
[0117] In another aspect, the present invention provides a chimeric antigen receptor comprising an extracellular antigen binding unit, a transmembrane domain and an intracellular domain as described herein. As used herein, the term "chimeric antigen receptor (CAR)" refers to a tumor antigen binding structural domain fused to an intracellular signaling domain and capable of activating T cells. Typically, the extracellular binding domain of the CAR is derived from a mouse or humanized or human monoclonal antibody.
[0118] A chimeric antigen receptor typically comprises an extracellular antigen-binding domain or antigen-binding unit, which in some embodiments is an antigen-binding unit as described herein above.
[0119] In some embodiments, the extracellular antigen binding region may be fully human. In other cases, the extracellular antigen binding region may be humanized. In other cases, the extracellular antigen binding region may be murine or chimeric in the extracellular antigen binding region may consist of amino acid sequences from at least two different animals. In some embodiments, the extracellular antigen binding region may be non-human. A wide variety of antigen-binding regions can be designed. Non-limiting examples include single chain variable fragments (scFv) from antibodies, fragment antigen-binding regions (Fab) selected from a library, single domain fragments, or natural ligands conjugated to their cognate receptors. In certain embodiments, the extracellular antigen-binding region can include scFv, Fab, or natural ligands, and any derivatives thereof. The extracellular antigen-binding region can include a portion of an intact antibody and can refer to a molecule other than an intact antibody that can bind to an antigen bound by the intact antibody. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2, bifunctional antibodies, linear antibodies, single chain antibody molecules (e.g., scFv), and multispecific antibodies formed from antibody fragments.
[0120] The extracellular antigen binding region, such as scFv, Fab or natural ligand, may be the part of the CAR that determines the antigen specificity. The extracellular antigen binding region may bind to any complementary target. The extracellular antigen binding region may be derived from an antibody with a known variable region sequence. The extracellular antigen binding region may be obtained from an antibody sequence from an available mouse hybridoma. Alternatively, the extracellular antigen binding region may be obtained via the entire external cleavage sequence of a tumor cell or a primary cell, such as a tumor infiltrating lymphocyte (TIL). In certain embodiments, the binding specificity of the extracellular antigen-binding region can be determined by the complementarity determining regions or CDRs, such as the light chain CDRs or the heavy chain CDRs. In many cases, the binding specificity can be determined by the light chain CDRs and the heavy chain CDRs. A given combination of heavy and light chain CDRs can provide a given binding pocket that can confer greater affinity and / or specificity to the antigen compared to other reference antigens.
[0121] In some aspects of any embodiment disclosed herein, the extracellular antigen-binding region, such as an scFv, can comprise a light chain CDR specific for the antigen. The light chain CDR can be a complementarity determining region of an antigen-binding unit, such as an scFv light chain of a CAR. The light chain CDR can comprise a contiguous amino acid residue sequence or two or more contiguous amino acid residue sequences of amino acid residues separated by non-complementarity determining regions (e.g., framework regions). In some embodiments, the light chain CDR can comprise two or more light chain CDRs, which can be designated as light chain CDR-1, CDR-2, etc. In some embodiments, the light chain CDR can comprise three light chain CDRs, which can be designated as light chain CDR-1, light chain CDR-2, and light chain CDR-3. In some embodiments, the set of CDRs present on a common light chain can be collectively designated as light chain CDRs.
[0122] In some aspects of any embodiment disclosed herein, an extracellular antigen-binding region, such as an scFv, can comprise a heavy chain CDR specific for an antigen. The heavy chain CDR can be an antigen-binding unit, such as a heavy chain complementarity determining region of an scFv. The heavy chain CDR can comprise a contiguous amino acid residue sequence or two or more contiguous amino acid residue sequences of amino acid residues separated by non-complementarity determining regions (e.g., framework regions). In some embodiments, the heavy chain CDR can comprise two or more heavy chain CDRs, which can be named heavy chain CDR-1, CDR-2, etc. In some embodiments, the heavy chain CDR can comprise three heavy chain CDRs, which can be named heavy chain CDR-1, heavy chain CDR-2, and heavy chain CDR-3. In some embodiments, a set of CDRs present on a common heavy chain can be collectively named heavy chain CDRs.
[0123] The extracellular antigen-binding region can be modified in various ways by genetic engineering. In some embodiments, the extracellular antigen-binding region can be mutated so that the extracellular antigen-binding region can be selected to have a higher affinity for its target. In some embodiments, the affinity of the extracellular antigen-binding region for its target can be optimized for targets that are expressed at low levels on normal tissues. This optimization can be performed to minimize potential toxicity. In other cases, clones of extracellular antigen-binding regions with higher affinity for the membrane-bound form of the target can be preferred over its soluble counterpart. Such modifications can be performed because targets with different levels of soluble form can also be detected, and targeting them may cause undesirable toxicity.
[0124] In some embodiments, the extracellular antigen-binding region comprises a hinge or spacer region. The terms "hinge" and "spacer region" can be used interchangeably. The hinge can be considered as a part of the CAR to provide flexibility to the extracellular antigen-binding region. In some embodiments, the hinge can be used to detect the CAR on the cell surface, especially when an antibody that detects the extracellular antigen-binding region is ineffective or available. For example, it may be necessary to optimize the length of the hinge derived from the immunoglobulin depending on the location of the epitope on the target that the extracellular antigen-binding region targets. In one embodiment, the hinge may not belong to an immunoglobulin, but to another molecule, such as the natural hinge of the CD8α molecule. The CD8α hinge may contain cysteine and proline residues that are known to play a role in the interaction of the CD8 coreceptor with the MHC molecule. Said cysteine and proline residues may affect the performance of the CAR.
[0125] The CAR hinge is tunable in size. This form of immunological synapse between immune response cells and target cells further limits the distance that cannot be functionally bridged by the CAR for membrane-distal epitopes on the target molecule at the cell surface, and even with a short hinge CAR, the synaptic distance cannot reach an approximate value that can transmit a signal. Similarly, the target antigen epitope of the membrane-proximal CAR is observed to have a signal output in the background of a long hinge CAR. The hinge can be adjusted depending on the extracellular antigen binding region used. The hinge can be of any length.
[0126] The transmembrane domain can anchor the CAR to the plasma membrane of the cell. The native transmembrane portion of CD28 can be used in the CAR. In other cases, the native transmembrane portion of CD8α can also be used in the CAR. "CD8" can be a protein having at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to NCBI Reference No. NP_001759 or a fragment thereof having stimulatory activity. A "CD8 nucleic acid molecule" can be a polynucleotide encoding a CD8 polypeptide, and in some cases, the transmembrane region can be the native transmembrane portion of CD28, and "CD28" can be a protein having at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to NCBI Reference No. NP_006130 or a fragment thereof having stimulatory activity. A "CD28 nucleic acid molecule" can be a polynucleotide encoding a CD28 polypeptide. In one embodiment, the transmembrane portion can include a CD8α region.
[0127] The intracellular signaling region of the CAR can be involved in activating at least one effector function of the immune response cell in which the CAR is placed. The CAR can induce an effector function of a T cell, for example, the effector function is a cytolytic activity or a helper activity, including the secretion of cytokines. Thus, the term intracellular signaling region refers to a protein portion that transmits an effector function signal and directs the cell to perform a specific function. Although the entire intracellular signaling region can generally be used, it is often not necessary to use the entire chain of the signal domain. In some embodiments, a truncated portion of the intracellular signaling region is used. In some embodiments, the term intracellular signaling region is meant to include any truncated portion of the intracellular signaling region that is sufficient to transmit an effector function signal in this sense.
[0128] Preferred embodiments of signal domains used in CARs can include the cytoplasmic sequences of a T cell receptor (TCR) and a co-receptor that act synergistically to initiate signal transduction following target-receptor binding, and any derivative or mutant sequences thereof, and any synthetic sequences having the same functionality of such sequences.
[0129] In some embodiments, the intracellular signaling region can include a known signaling motif of an immunoreceptor tyrosine-based activation motif (ITAM). Exemplary ITAMs that contain cytoplasmic signaling sequences include those derived from TCRζ, FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD5, CD22, CD79a, CD79b, and CD66d. However, in a preferred embodiment, the intracellular signaling domain is derived from the CD3ζ chain.
[0130] An example of a T cell signaling domain containing one or more ITAM motifs is the CD3ζ domain, also called the T cell receptor T3ζ chain or CD247. This domain is part of the T cell receptor-CD3 complex and plays an important role in coupling several intracellular signaling pathways with antigen recognition and the primary effector activation of T cells. As used herein, CD3ζ refers primarily to human CD3ζ and its isoforms, including proteins with substantially identical sequences as known from Swissprot accession P20963. It is reiterated that as part of the chimeric antigen receptor, the entire T cell receptor T3ζ chain is not required, and any derivative of the signaling domain of the T cell receptor T3ζ chain, including any functional equivalent thereof, is entirely suitable.
[0131] The intracellular signaling domain can be selected from any of the domains in Table 1. In certain embodiments, the domain can be modified such that it can have between about 50% and about 100% identity with the reference domain. Any of the domains in Table 1 can be modified such that the modified form can include about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or up to about 100% identity.
[0132] The intracellular signaling region of the CAR can further include one or more costimulatory domains. The intracellular signaling region can include a single costimulatory domain, such as the zeta chain (first generation CAR) or CD28 or 4-1BB (second generation CAR). In another embodiment, the intracellular signaling region can include two costimulatory domains, such as CD28 / OX40 or CD28 / 4-1BB (third generation).
[0133] Together with intracellular signaling domains such as CD8, these costimulatory domains can trigger downstream activation of kinase pathways to support gene transcription and functional cellular responses. The costimulatory domain of CAR can activate proximal signaling proteins involved in the CD28 (phosphatidylinositol-4,5-diphosphate 3-kinase) or 4-1BB / OX40 (TNF-receptor associated factor adaptor protein) pathways and MAPK and Akt activation.
[0134] In some cases, the signal generated by the CAR can be combined with an auxiliary or costimulatory signal. For the costimulatory signaling domain, the chimeric antigen receptor-like complex can be designed to include several possible costimulatory signal domains. As is well known in the art, in naive T cells, the engagement of the T cell receptor alone is not sufficient to induce the complete activation of T cells into cytotoxic T cells. Full productive T cell activation requires a second costimulatory signal. Several receptors have been reported to provide costimulation for T cell activation, including but not limited to CD28, OX40, CD27, CD2, CD5, ICAM-1, LFA-1 (CD11a / CD18), 4-1BBL, MyD88 and 4-1BB. The signaling pathways used by these costimulatory molecules can act synergistically with the main T cell receptor activation signal. The signals provided by these costimulatory signaling regions can act synergistically with the main effect activation signal derived from one or more ITAM motifs (e.g., CD3ζ signaling domain) to complete the requirements for T cell activation.
[0135] In some embodiments, the addition of a costimulatory domain of a chimeric antigen receptor-like complex can enhance the efficacy and durability of the engineered cells. In other embodiments, the T cell signaling domain and the costimulatory domain are fused to each other to form the signaling region.
[0136] TIFF0007587921000004.tif234170TIFF0007587921000005.tif117170
[0137] The chimeric antigen receptor binds to a target antigen. When T cell activation is measured in vitro or ex vivo, the target antigen can be obtained or isolated from various sources. As used herein, a target antigen is an antigen or an immune epitope on an antigen that is important for immune recognition and ultimately for elimination or control of a pathogenic agent or disease state in a mammal. The immune recognition can be cellular and / or bodily fluid. In the case of intracellular pathogens and cancer, the immune recognition can be, for example, a T lymphocyte response.
[0138] In some embodiments, the target antigen includes an antigen associated with a precancerous or proliferative condition. The target antigen can also be associated with or caused by cancer. For example, in some embodiments, the chimeric antigen receptors of the invention recognize and bind tumor antigens of the TSAs and TAAs described herein.
[0139] In some embodiments, the chimeric antigen receptor of the present invention is present on the plasma membrane of a cell, and when it binds to its target and is activated, the cell expressing the chimeric antigen receptor can cause cytotoxicity against the cell bearing the target.For example, in some embodiments, the chimeric antigen receptor is present on a cytotoxic cell, such as a NK cell or a cytotoxic T cell, and when it is activated by a target, the cytotoxic cell can increase the toxicity against the target cell.In some embodiments, the chimeric antigen receptor of the present invention can increase the action of immune response cells against cells expressing claudin 18A2, such as tumor cells. In some embodiments, the cytotoxic effect of a cell expressing a chimeric antigen receptor described herein against a cell expressing claudin 18A2 is improved by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 1-fold, at least 1.5-fold, at least 2-fold, at least 2.5-fold, at least 3-fold, at least 3.5-fold, at least 4-fold, at least 4.5-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, or at least 10-fold compared to a cell not expressing a chimeric antigen receptor described herein.
[0140] In one embodiment, the chimeric antigen receptor herein is present on the plasma membrane of a cell, and when bound to its target and activated, does not induce significant cytotoxicity in cells that contain the claudin 18A1 peptide but do not contain the claudin 18A2 peptide. In one embodiment, the cytotoxicity level is less than 10%, 5%, 4%, 3%, 2% or 1%.
[0141] A transgene that encodes a receptor or CAR that binds a target antigen can be incorporated into a cell. For example, the transgene can be incorporated into an immune response cell, such as a T cell. When inserted into a cell, the transgene can be a complementary DNA (cDNA) fragment that is a copy of messenger RNA (mRNA), or it can be a gene itself (with or without introns) located in the original region of its genomic DNA.
[0142] The nucleic acid encoding the transgene sequence, such as DNA, can be randomly inserted into the chromosome of the cell. Random integration can occur by any method of introducing nucleic acid (e.g., DNA) into the cell. For example, such methods can include, but are not limited to, electroporation, ultrasound, the use of a gene gun, lipofection, calcium phosphate transfection, the use of dendrimers, microinjection and the use of viral vectors, including adenovirus, AAV and retrovirus vectors, and / or type II ribozymes.
[0143] The DNA encoding the transgene may be further designed to contain a reporter gene, such that the presence of the transgene or its expression product can be detected by activation of the reporter gene. Any reporter gene can be used, such as those described above. Cells containing the transgene can be selected by selecting cells in the cell culture in which the reporter gene is already activated.
[0144] The expression of CAR can be verified, for example, by expression assays such as qPCR, or by measuring the level of RNA. The expression level can also indicate copy number. For example, if the expression level is very high, this can indicate that one or more copies of CAR have been integrated into the genome. Or high expression can indicate that the transgene is integrated into a highly transcribed region, such as near a highly expressed promoter. It can also be verified by measuring protein levels, for example, by Western blotting.
[0145] In some embodiments, the immune response cell of the present invention can include one or more transgenes. The one or more transgenes can express a CAR protein that recognizes and binds at least one epitope on an antigen or binds to a mutant epitope on an antigen. The CAR can be a functional CAR. In some embodiments, the immune response cell of the present invention can include one or more CARs, or it can include a single CAR and a second engineered receptor.
[0146] In some embodiments, the transgene can code for a suicide gene. As evidenced by many effective treatments for cancer patients, CAR immune response cells can cause tumor regression but with associated toxicity. In some embodiments, when the target immunogen coexists in normal tissue and tumor cells, the CAR immune response cells cannot distinguish between tumor and normal tissue ("on-target / off-target toxicity"). In some cases, a global disruption of the immune system can occur, called cytokine release syndrome (CRS). The CRS can include a systemic inflammatory response syndrome or cytokine storm, which can be the result of rapid expansion of CAR immune response cells in vivo. CRS is a condition characterized by fever and low blood pressure, and in severe cases can cause multiple organ failure. In most cases, the toxicity is associated with the expansion of the infused CAR immune response cells in vivo, which can cause a global disruption of the immune system and release high levels of proinflammatory cytokines such as TNFα and IL-6. The suicide gene can induce elimination of CAR immune response cells. The suicide gene can be any gene that induces apoptosis in the CAR immune response cells. A suicide gene can be encoded in the viral vector along with the antigen-binding receptor, which allows mitigation or complete abolition of toxicity caused by in vivo expansion of the injected CAR immune response cells under certain conditions.
[0147] In one embodiment, CAR-immunoreactive cells present in normal tissue antigens can be made to transiently express the CAR, for example after electroporation of the receptor-encoding mRNA, and further enriched for CAR-immunoreactive cells by including a safety switch, allowing for the elimination of many CAR-immunoreactive cells in the event of severe target toxicity.
[0148] In certain embodiments, the CAR-encoding vector can be combined with, for example, an inducible caspase 9 gene (activated by a chemical inducer of the dimer) or a truncated EGF receptor R (activated by the monoclonal antibody cetuximab) or an RQR8 safety switch.
[0149] As used herein, the one or more transgenes can be from different species. For example, the one or more transgenes can include human genes, mouse genes, rat genes, pig genes, cow genes, dog genes, cat genes, monkey genes, chimpanzee genes, or any combination thereof. For example, the transgene can be of human origin with human genetic sequence. The one or more transgenes can include human genes. In some cases, the one or more transgenes are not adenovirus genes.
[0150] As described above, the transgene can be inserted randomly or site-specifically into the genome of the immune-responsive cell, for example, the transgene can be inserted into a random site in the genome of the immune cell. Such a transgene can be functional, for example, fully functional when inserted into any part of the genome. For example, the transgene can code for its own promoter or can be inserted into a position controlled by its internal promoter. Alternatively, the transgene can be inserted into a gene, such as an intron of the gene or an exon of the gene, a promoter or a non-coding region. The insertion of the transgene can disrupt a gene, such as an endogenous immune checkpoint.
[0151] In some embodiments, one or more copies of the transgene can be inserted into multiple random sites in the genome. For example, multiple copies can be inserted into random sites in the genome. This may increase overall expression compared to a single random insertion of the transgene. Alternatively, a copy of the transgene can be inserted into a gene and another copy of the transgene can be inserted into a different gene. The transgene can be targeted so that it can be inserted into a specific site in the genome of the immunoreactive cell.
[0152] In some embodiments, the polynucleic acid comprising a sequence encoding an antigen-binding receptor can take the form of a plasmid vector. The plasmid vector can include a promoter. In some cases, the promoter can be constitutive. In some embodiments, the promoter is inducible. The promoter can be CMV, U6, MND, or EF1a, or can be derived therefrom. In some embodiments, the promoter can be adjacent to a CAR sequence. In some embodiments, the plasmid vector further comprises a splice acceptor. In some embodiments, the splice acceptor can be adjacent to a CAR sequence. The promoter sequence can be a PKG or MND promoter. The MND promoter can be a synthetic promoter comprising the U3 region of MoMuLV LTR modified with a myeloproliferative sarcoma virus enhancer.
[0153] In some embodiments, polynucleic acids encoding target receptors can be designed to be delivered to cells by non-viral techniques. In some cases, the polynucleic acids may be good manufacturing practice (GMP) compatible reagents.
[0154] The expression of the polynucleotide encoding the target-binding antigen receptor or CAR can be controlled by one or more promoters. The promoter can be a commonly occurring constitutive type (unrestricted promoter that allows continuous transcription of the relevant gene), a tissue-specific promoter, or an inducible promoter. The expression of the transgene inserted adjacent to or close to the promoter can be regulated. For example, the transgene can be inserted near or next to a commonly occurring promoter. Some commonly occurring promoters can be the CAGGS promoter, the hCMV promoter, the PGK promoter, the SV40 promoter, or the ROSA26 promoter.
[0155] The promoter may be endogenous or exogenous. For example, one or more transgenes may be inserted adjacent or close to the endogenous or exogenous ROSA26 promoter. The promoter may be specific to immunoreactive cells. For example, one or more transgenes may be inserted adjacent or close to the porcine ROSA26 promoter.
[0156] Tissue-specific or cell-specific promoters can be used to control the location of expression. For example, one or more transgenes can be inserted adjacent to or close to a tissue-specific promoter. The tissue-specific promoter can be FABP promoter, LckC promoter, CamKII promoter, CD19 promoter, keratin promoter, albumin promoter, aP2 promoter, insulin promoter, MCK promoter, MyHC promoter, WAP promoter or Col2A promoter.
[0157] Inducible promoters may also be used. These inducible promoters can be turned on and off by adding or removing an inducer as needed. Predictive inducible promoters may be, but are not limited to, Lac, tac, trc, trp, araBAD, phoA, recA, proU, cst-1, tetA, cadA, nar, PL, cspA, T7, VHB, Mx, and / or Trex.
[0158] The term "inducible promoter" as used herein refers to a regulated promoter that does not express or expresses at a low level a gene operably linked thereto before a desired condition is reached, and expresses or expresses at a high level a gene operably linked thereto when the desired condition is reached. For example, in an embodiment, the inducible promoter of the present application does not express or expresses at a low level a gene operably linked thereto under normal or high oxygen conditions in a cell, and expresses or expresses at a high level a gene operably linked thereto under low oxygen conditions in response to a decrease in oxygen content in the cell. In an embodiment, the inducible promoter used herein comprises Hypoxia-Inducible Transcription factor-1α (HIF-1α). In one embodiment, the term "inducible promoter" as used herein refers to an "immune cell-inducible promoter" that does not express or expresses a gene operably linked thereto at a low level before an immune response cell contacts an antigen or when the immune response cell is not activated, and drives a gene operably linked thereto at a high level of expression or under conditions such as hypoxia only when the immune response cell contacts an antigen or when the immune response cell is activated. In one embodiment, the "immune cell-inducible promoter" includes an NFAT (nuclear factor of activated T cells)-type promoter.
[0159] As used herein, "NFAT-type promoter" refers to a promoter that regulates the expression of a gene operably linked to it based on NFAT binding activity.
[0160] NFAT is a general term for a family of transcription factors that play an important role in immune responses. One or more members of the NFAT family are expressed in most cells of the immune system. NFAT is also involved in the development of the heart, skeletal muscle, and nervous system.
[0161] The NFAT transcription factor family consists of five members, NFAT1, NFAT2, NFAT3, NFAT4 and NFAT5. NFAT1-NFAT4 are regulated by calcium signals. Calcium signals are important for the activation of NFAT because calmodulin (CaM) activates the serine / threonine phosphatase calcineurin (CN). Activated CN rapidly dephosphorylates the repeat sequences of the serine-rich region (SRR) and SP in the amino terminus of the NFAT protein, changing its structure and exposing the nuclear localization signal, which allows NFAT to enter the nucleus.
[0162] Based on the role of NFAT in the transcriptional expression of cytokines during T cell activation, the immune cell-inducible promoters described herein can be used to regulate expression or high levels of genes operably linked thereto when immune response cells contact an antigen and become activated.
[0163] The nucleic acid of the present invention may comprise any suitable nucleotide sequence encoding a NFAT-type promoter (or a functional portion or functional variant thereof). As used herein, "NFAT-type promoter" refers to one or more NFAT response elements linked to a minimal promoter of any gene expressed by a T cell. Preferably, the minimal promoter of a gene expressed by a T cell is the smallest human IL-2 promoter. The NFAT response element may comprise, for example, NFAT1, NFAT2, NFAT3 and / or NFAT4 response elements. In some embodiments, the "NFAT-type promoter" described herein comprises one or more motifs that bind to NFAT. For example, the "NFAT-type promoter" may comprise 2, 3, 4, 5, 6, 7, 8, 9, 10 or more NFAT binding motifs. In some embodiments, the "NFAT-type promoter" comprises up to 12 NFAT binding motifs. In some embodiments, the "NFAT-type promoter" may be a promoter in which multiple NFAT binding motifs are configured in series with a promoter such as the IL2 minimal promoter. In one embodiment, the NFAT-type promoter described herein comprises six NFAT binding motifs, referred to as (NFAT)6. For convenience, the (NFAT)6 is also referred to as NFAT6. In one embodiment, the NFAT6 also represents six repeated NFAT binding motifs (SEQ ID NO:94) in the NFAT-type promoter.
[0164] In addition, the transgene sequence may also include transcriptional or translational regulatory sequences, such as a promoter, enhancer, insulator, internal ribosome entry site, a sequence encoding a 2A peptide, and / or a polyadenylation signal, which are not essential for expression.
[0165] In some embodiments, the transgene encodes a receptor for a target binding antigen or a CAR, where the transgene is inserted into a safe harbor such that the receptor for said binding antigen is expressed. In some embodiments, the transgene is inserted into the PD1 and / or CTLA-4 locus. In other cases, the transgene is delivered to the cell as a lentivirus and inserted randomly, and the PD1 or CTLA-4 specific nuclease can be provided as an mRNA. In some embodiments, the transgene is delivered by a viral vector system such as a retrovirus, AAV or adenovirus and an mRNA encoding a nuclease specific for the safe harbor (e.g., AAVS1, CCR5, albumin or HPRT). The cell can be treated with an mRNA encoding a PD1 and / or CTLA-4 specific nuclease. In some embodiments, a polynucleotide encoding a CAR is provided together with a viral delivery system and an mRNA encoding an HPRT specific nuclease and a PD1- or CTLA-4 specific nuclease. CARs with which the methods and compositions disclosed herein can be used include all types of these chimeric proteins.
[0166] In some embodiments, a retroviral vector (γ-retrovirus or lentivirus vector) can be used to introduce a transgene into an immunoreactive cell. For example, a gene encoding a CAR or any receptor that binds to an antigen, or a variant or fragment thereof, can be cloned into a retroviral vector and driven by its endogenous promoter, the retroviral long terminal repeat, or a promoter specific to the target cell type. Non-viral vectors can also be used. Non-viral vector delivery systems can include DNA plasmids, exposed nucleic acid, and nucleic acid complexed with a delivery vector such as liposomes or poloxamers.
[0167] Many virus-based systems have been developed to transfer genes into animal cells. For example, retroviruses have provided a convenient platform for gene delivery systems. The selected gene is inserted into a vector and packaged into retroviral particles using techniques known in the art. Vectors derived from retroviruses, such as lentiviruses, are suitable tools for achieving long-term gene transfection, since they allow long-term stable integration of the genetic modification and propagation in daughter cells. Lentiviral vectors have an additional advantage over vectors derived from retroviruses, such as murine leukemia viruses, since they can transduce non-proliferating phagocytes. They further have the added advantage of low immunogenicity. The advantage of adenoviral vectors is that they are not fused to the genome of the target cell, bypassing negative integration-related events.
[0168] The cells can be transfected with a transgene encoding a receptor that binds to the antigen. The transgene concentration can be about 100 pg to about 50 μg. In some embodiments, the amount of nucleic acid (e.g., ssDNA, dsDNA, or RNA) introduced into the cells can be varied to optimize transfection efficiency and / or cell vitality. For example, 1 μg of dsDNA can be used for electroporation in each cell sample. In some embodiments, the amount of nucleic acid (e.g., double-stranded DNA) required for optimal transfection efficiency and / or cell vitality varies depending on the cell type. In some embodiments, the amount of nucleic acid (e.g., dsDNA) used in each sample can directly correspond to transfection efficiency and / or cell vitality. For example, it is the same as a series of transfection concentrations. The transgene encoded by the vector can be integrated into the genome of the cell. In some embodiments, the transgene encoded by the vector is integrated in all directions. In other cases, the transgene encoded by the vector is retrointegrated.
[0169] The vector is delivered to each patient's body, usually via systemic administration (e.g., intravenous, intraperitoneal, intramuscular, subcutaneous or intracranial injection) or local application, as described below. Alternatively, the vector can be delivered to cells in vitro, for example after removing cells from each patient (e.g., lymphocytes, T cells, bone marrow aspirates, tissue biopsies), usually after selecting and transfecting the cells into which the vector has been inserted, the cells are then transplanted back into the patient. Cells can be expanded before or after selection.
[0170] Suitable immunoreactive cells expressing a receptor bound to the antigen may be cells autologous or non-autologous to the individual in need.
[0171] A suitable source of immune response cells can be obtained from an individual. In some cases, T cells can be obtained. The T cells can be obtained from a variety of sources, including PBMC, bone marrow, lymphoma tissue, umbilical cord blood, thymus tissue and tissue from infected sites, ascites, pleural fluid, spleen tissue, and tumor tissue. In some cases, T cells can be obtained from collected blood from the individual using any number of techniques known to those skilled in the art, such as Ficoll™ separation. In some embodiments, a single blood draw is used to obtain cells circulating in the blood of an individual. A single blood draw product typically contains lymphocytes, including T cells, mononuclear cells, granulocytes, B cells, other nucleated white blood cells, red blood cells, and platelets. In some embodiments, the cells collected from a single blood draw can be washed to remove the plasma fraction and left in an appropriate buffer or medium for subsequent processing steps.
[0172] Alternatively, the cells can be derived from a healthy donor, a patient diagnosed with cancer or a patient diagnosed with an infection. In some embodiments, the cells can be part of a mixed cell population with different phenotypic characteristics. The cell line can be obtained from transformed T cells according to the methods described above. The cells can also be obtained from a library of cell therapy. Modified cells that are resistant to immunosuppressive treatment can be obtained by any of the methods described herein above. The appropriate cell population can be selected before modification. The artificial cell population can be selected after modification. The artificial cells can be used for autologous transplantation. Alternatively, the cells can be used for allogeneic transplantation. In some embodiments, the cells are applied to the same patient as the sample for testing the cancer-associated target sequence. In other cases, the cells are applied to a patient different from the patient whose sample is used to validate the cancer-associated target sequence.
[0173] In some embodiments, the primary cells of choice include peripheral blood mononuclear cells (PBMCs), peripheral blood lymphocytes (PBLs) and other blood cell subpopulations, including but not limited to T cells, natural killer cells, monocytes, natural killer T cells, monocyte progenitors, hematopoietic stem cells or non-pluripotent stem cells. In some embodiments, the cells may be any immune cell, including any T cell, such as tumor infiltrating cells (TILs), for example, CD3+ T cells, CD4+ T cells, CD8+ T cells or any other type of T cell. The T cells may include memory T cells, memory stem T cells or effector T cells. The T cells may be selected from a large population, for example, from whole blood. The T cells may be expanded from a large population. The T cells may be predisposed to a particular population and phenotype. For example, T cells can be predisposed to a phenotype that includes CD45RO(-), CCR7(+), CD45RA(+), CD62L(+), CD27(+), CD28(+) and / or IL-7Rα(+). Suitable cells can be one or more markers selected from CD45RO(-), CCR7(+), CD45RA(+), CD62L(+), CD27(+), CD28(+) and / or IL-7Rα(+). Suitable cells further include stem cells, such as embryonic stem cells, induced pluripotent stem cells, hematopoietic stem cells, neural stem cells and mesenchymal stem cells. Suitable cells can include any quantity of primary cells, such as human cells, non-human cells and / or murine cells. Suitable cells can be progenitor cells. Suitable cells can be derived from the subject to be treated (e.g., the patient).
[0174] The therapeutically effective amount of cells required for a patient can vary based on the viability of the cells and the efficiency with which the cells are genetically modified (e.g., the efficiency with which a transgene is integrated into one or more cells, or the expression level of a protein encoded by the transgene). In some embodiments, the product (e.g., fold increase) of the viability of the cells after genetic modification and the efficiency of transgene integration can correspond to a therapeutic amount of cells administered to a subject. In some embodiments, an increase in the viability of the cells after genetic modification can correspond to a decrease in the amount of cells required to administer to a patient for effective treatment. In some embodiments, an increase in the efficiency of transgene integration in one or more cells can correspond to a decrease in the amount of cells required for therapeutically effective administration in a patient. In some embodiments, determining the amount of therapeutically effective cells required can include determining a function associated with the change in the cells as a function of time. In some embodiments, determining the amount of therapeutically effective cells required can include determining a function associated with the change in the efficiency of transgene integration into one or more cells due to a time-related variable (e.g., cell culture time, electroporation time, stimulation time of cells). In some embodiments, a therapeutically effective cell can be a population of cells that comprises expression of an antigen-bound receptor on the cell surface from about 30% to about 100%. In some embodiments, a therapeutically effective cell can express the antigen-bound receptor on more than about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% or about 99.9% of the cell surface as measured by flow cytometric analysis.
[0175] According to one aspect of the invention, the invention also includes a nucleic acid encoding a receptor that binds to said antigen. The invention also relates to variants of said polynucleotides, which encode polypeptides of the same amino acid sequence as the invention or fragments, analogs and derivatives of the polypeptides.
[0176] The invention further provides a vector comprising a nucleic acid encoding a receptor protein that binds to an antigen expressed on the surface of said immune response cell.
[0177] The present invention further includes viruses that contain the vectors. The viruses of the present invention include infectious viruses after packaging, and also packaged viruses that contain the necessary components to be packaged into infectious viruses. Other viruses and their corresponding plasmid vectors that can be used to transduce exogenous genes into immune response cells known in the art can also be used in the present invention.
[0178] In another aspect, the present specification provides a host cell, comprising an antigen binding unit or chimeric antigen receptor described herein and any type I interferon. In another aspect, the present specification provides a host cell, comprising a nucleic acid encoding an antigen binding unit or chimeric antigen receptor described herein and any type I interferon.
[0179] In some embodiments, the host cell is an immune response cell. In some embodiments, the immune response cell is a T cell, a natural killer cell, a cytotoxic T lymphocyte, a natural killer T cell, a DNT cell, and / or a regulatory T cell. In some embodiments, the host cell is an NK92 cell.
[0180] In one embodiment, an expression construct can be included in the immune response cell of the present invention, and the expression construct has elements connected sequentially and consecutively, such as an antibody, a CD28 costimulatory signal domain, CD3ζ, and an expression unit of NFAT6, type I interferon, connected in the opposite direction to the above-mentioned elements. Preferably, the antibody and the costimulatory signal domain of CD28 are connected via the CD8α transmembrane domain and the hinge region of CD8α.
[0181] In one embodiment, activation of nuclear factor of activated T cells (NFAT) plays an important role in transcriptional expression of cytokines during the activation of T cells. In view of this, the present inventors have demonstrated that by placing the IFN-beta coding sequence under the control of the NFAT6 promoter, IFN-beta can be expressed at high levels only when CAR-T cells come into contact with an antigen and T cells are activated.
[0182] The NFAT6 promoter is a promoter that consists of six NFAT-binding sites and the IL2 minimal promoter linked in series (Hooijberg E, Bakker AQ, Ruizendaal JJ, Spits H. NFAT-controlled expression of GFP permits visualization and isolation of antigen-stimulated primary human T cells. Blood. 2000 Jul 15;96(2):459-66), and can be used to regulate the expression of cytokines such as IL12 in T lymphocytes such as TCR-T (Zhang L, Kerkar SP, Yu Z, Zheng Z, Yang S, Restifo NP, Rosenberg SA, Morgan RA. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther.2011 Apr;19(4):751-9).
[0183] The immune response cells of the present invention are transduced with a construct or expression vector expressing an antigen-bound receptor and an exogenous type I interferon, or a virus containing said plasmid. All of the conventional nucleic acid transduction methods in the art, including non-viral and viral transduction methods, can be used in the present invention.
[0184] The immune response cells of the present invention may further comprise coding sequences for exogenous cytokines, including but not limited to IL-12, IL-15, or IL-21. These cytokines may further have immunomodulatory or antitumor activity, improve the function of effector T cells and activated NK cells, or directly exert antitumor effects. Thus, those skilled in the art may understand that the use of these cytokines may help the immune response cells to exert their effects more effectively.
[0185] The immune response cells of the present invention may also express other receptors bound to antigens other than the receptor bound to the antigen.
[0186] The immune response cells of the present invention may also express chemokine receptors, including but not limited to CCR2. Those skilled in the art can understand that the CCR2 chemokine receptor can competitively bind to CCR2 in the body, which is advantageous in blocking tumor metastasis.
[0187] The immune response cells of the present invention may also express siRNA capable of reducing the expression of PD-1 or proteins capable of blocking PD-L1.Those skilled in the art will appreciate that competitively blocking the interaction of PD-L1 with its receptor PD-1 may favor the restoration of anti-tumor T cell responses and inhibit tumor growth.
[0188] The immune response cells of the present invention may further express a safety switch, preferably, the safety switch comprises iCaspase-9, Truncated EGFR or RQR8.
[0189] In one embodiment, the immune response cells of the invention do not express costimulatory ligands of this type, such as 4-1BBL.
[0190] Thus, in another aspect, the present specification provides a method of producing an antigen binding unit or chimeric antigen receptor as described herein, or a composition comprising same, comprising the step of culturing a host cell as described herein under suitable conditions, in one embodiment, the method further comprises isolating and obtaining an expression product of the host cell.
[0191] In another aspect, the present specification provides a composition comprising an antigen binding unit, chimeric antigen receptor, or nucleic acid described herein. In some embodiments, the composition is a pharmaceutical composition comprising the antigen binding unit, chimeric antigen receptor, or nucleic acid. In some embodiments, the pharmaceutical composition further comprises a pharma- ceutically acceptable vector.
[0192] In another aspect, the present specification provides a pharmaceutical composition comprising a host cell described herein and a pharma- ceutically acceptable vector.
[0193] The term "pharmaceutical acceptable" means that the molecules and compositions themselves do not produce adverse reactions, allergies or other side effects when administered appropriately to an animal or human.
[0194] In some embodiments, the composition includes another therapeutic agent. In some embodiments, the other therapeutic agent is, for example, those described in US20140271820, and / or pharma- ceutically acceptable salts or analogs thereof. In some embodiments, the therapeutic agent is a mitotic inhibitor (vinca alkaloid), including vincristine, vinblastine, vindesine, novibin (TM) (vinorelbine, 5'-dehydrohydrogen sulfide); Camptosar TM (Irinotecan HCL), Hycamtin TMtopoisomerase I inhibitors such as the compounds of camptothecin (topotecan HCL) and other compounds derived from camptothecin and its analogs; podophyllotoxin derivatives such as etoposide, teniposide, and midozozo; the alkylating agent cisplatin, cyclophosphamide, nitrogen mustard, trimethylene thiophosphoramide, carmustine, busulfan, chlorambucil, briquetazine, and uracil mustard. antimetabolites including mustard, clopropene, and dacarbazine; cytarabine, 5-fluorouracil, methotrexate, guanidine, azathioprine, and procarbazine; doxorubicin, bleomycin, dactinomycin, and daunorubicin. antibiotics, including but not limited to, mycinmycin, mitomycin, sarkomeric C, and daunorubicin; and other therapeutic agents, including but not limited to, antitumor antibodies, dacarbazine, cytidine, amushakang, melphalan, isophosphamide, and mitoxantrone. In some embodiments, the other therapeutic agents are selected from one or more of epirubicin, oxaliplatin, and 5-fluorouracil.In certain embodiments, the other therapeutic agents include, but are not limited to, antiangiogenic agents, including anti-VEGF antibodies (humanized and chimeric antibodies, anti-VEGF aptamers, and antisense oligonucleotides), and other antiangiogenic agents, such as angiostatin, endostatin, interferon, interferon 1 (including α and β), interleukin 12, retinoic acid, tissue inhibitors of metalloproteinases-1, and protease-2.
[0195] Specific examples of substances that may be pharma- ceutically acceptable as part of the vector or its components include sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and derivatives such as carboxymethyl cellulose, ethyl cellulose, and methyl cellulose; tragacanth gum powder; malt; solid lubricants such as gelatin, talc, stearic acid, and magnesium stearate; calcium sulfate, vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil, and cocoa oil; polyols such as propylene glycol, glycerin, sorbitol, mannitol, and polyethylene glycol; emulsifiers such as alginic acid and Tween; sodium lauryl sulfate; lauryl sulfate); colorants, flavoring agents, compressed tablets, stabilizers, antioxidants, preservatives, pyrogen-free water, isotonic saline, phosphate buffer, etc.
[0196] The pharmaceutical compositions described herein may contain one or more pharma- ceutically acceptable salts. A "pharma-ceutically acceptable salt" refers to a salt that retains the desired biological activity of the parent compound and does not induce adverse toxicological effects (see, for example, Berge, SM, et al., J. Pharm. Sci. 66:1-19, 1977). Examples of such salts include acid addition salts and base addition salts.
[0197] Acid addition salts include salts derived from non-toxic inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, phosphorous acid, etc., and from non-toxic organic acids such as aliphatic monocarboxylic acids, dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyalkanoic acids, aromatic acids, aliphatic and aromatic sulfuric acids, etc. Base addition salts include salts derived from alkaline earth metals (e.g., sodium, potassium, magnesium, calcium, etc.), and from non-toxic organic amines such as N,N'-dibenzylethylenediamine, N-methylglucosamine, chloroprocaine, choline, diethanolamine, ethylenediamine, procaine, etc.
[0198] The pharmaceutical compositions described herein may further comprise an antioxidant. Examples of antioxidants include, but are not limited to, water-soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium hydrogen sulfate, sodium metabisulfite, and sodium sulfite; oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, and alpha-tocopherol; and metal chelators such as citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid, and phosphoric acid. The composition of the present invention can be prepared in various dosage forms as necessary, and can be administered to a patient in an amount determined by a doctor depending on factors such as the type, age, weight, and general disease state of the patient, and the administration method, etc. The administration method can be, for example, parenteral administration (e.g., injection) or other treatment methods.
[0199] "Parenteral" administration of the immunogenic compositions includes, for example, subcutaneous (sc), intravenous (iv), intramuscular (im) or intrasternal injection or infusion techniques.
[0200] The formulation containing the immunoreactive cell population administered to an individual contains a plurality of immunoreactive cells effective to treat and / or prevent a particular indication or disease. Thus, a therapeutically effective population of immunoreactive cells can be used in an individual. Typically, the therapeutically effective population of immunoreactive cells is about 1×10 4 pieces to about 1×10 10 In most cases, the preparation contains about 1×10 immune reactive cells. 5 From 1 x 10 pieces 9 Immunoreactive cells, approximately 5 x 10 5 Individual to approximately 5×108 immunoreactive cells or approximately 1 x 10 6 pieces to about 1×10 7 However, depending on the location, origin, status, extent, and severity of the cancer, and the age and physical condition of the individual being treated, the number of CAR immunoreactive cells administered to an individual may vary widely. The physician will ultimately determine the appropriate dose to be used.
[0201] In one embodiment, chimeric antigen receptors are used to stimulate immune cell-mediated immune responses. For example, T cell-mediated immune responses refer to immune responses activated by T cells. Activated antigen-specific cytotoxic T cells can induce apoptosis in target cells with exogenous antigen epitopes on the surface, such as cancer cells with tumor antigens. In another aspect of the present invention, chimeric antigen receptors are used to provide anti-tumor immunity in mammals. Due to the immune response mediated by T cells, anti-tumor immunity is generated in subjects.
[0202] In some cases, a method of treating a subject with cancer can involve administering to a subject in need of treatment one or more immune response cells according to the present invention. The immune response cells can bind to tumor targeting molecules and induce cancer cell death. As mentioned above, the present invention provides a method of treating a pathogen infection in an individual comprising administering to the individual a therapeutically effective amount of an immune response cell of the present invention.
[0203] The frequency of administration of the immune response cells of the present invention depends on the elements of the disease to be treated, the elements of the particular immune response cells and the administration method. For example, daily, 4th, 3rd, 2nd, or daily administration, once every 1st, 3rd, 4th, 5th, 6th days, once a week, once every 8th day, once every 9th day, once every 10th day, once a week or twice a month. As described herein, the immune response cells of the present invention have improved viability, so that they can be administered at a lower therapeutically effective dose than immune response cells of interferon that are similar but do not express exogenous type I interferon, but can also be administered less frequently and obtain at least similar, and preferably more pronounced, therapeutic effects.
[0204] In certain embodiments, the compositions can be isotonic, i.e., they can have the same osmotic pressure as blood or tears. The preferred isotonicity of the compositions of the present invention can be achieved using sodium chloride or other pharma- ceutically acceptable agents, such as glucose, boric acid, sodium tartrate, propylene glycol, or other inorganic or organic solutes. If necessary, the viscosity of the composition is maintained at a selected level using a pharma- ceutically acceptable thickening agent. Suitable thickening agents include, for example, methylcellulose, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, carbomer, and the like. The desired concentration of the thickening agent is determined by the agent selected. Thus, the selection of the appropriate vector and other additives is determined by the exact route of administration and the nature of the particular formulation, such as a liquid formulation.
[0205] The present invention provides a kit comprising an antigen binding unit, a chimeric antigen receptor, a nucleic acid or an immune response cell described herein. In some embodiments, the kit can comprise a composition for treating or preventing the antigen binding unit, a chimeric antigen receptor, a nucleic acid or an immune response cell described herein, comprising one or more unit dosage forms comprising an effective amount. In some embodiments, the kit can comprise a sterile container containing the therapeutic or prophylactic composition, which can be in the form of a cartridge, an ampule, a bottle, a vial, a tube, a bag, a blister pack or other suitable container known in the art. These containers can be made of plastic, glass, laminated paper, metal foil, or other materials suitable for holding drugs. In some embodiments, the kit comprises an antigen binding unit, a chimeric antigen receptor, a nucleic acid or an immune response cell described herein, and instructions for administering the antigen binding unit, a chimeric antigen receptor, a nucleic acid or an immune response cell described herein to an individual. The instructions generally include a method for treating or preventing cancer or tumors using the antigen binding unit, a chimeric antigen receptor, a nucleic acid or an immune response cell described herein. In one embodiment, the kit comprises a host cell described herein, the host cell being about 1×10 4 Individual cells to approximately 1×10 6 In one embodiment, the kit comprises at least about 1×10 5 Individual cells, at least about 1 x 10 6 Individual cells, at least about 1 x 10 7 Individual cells, at least about 4 x 10 7 Individual cells, at least about 5 x 10 7 Individual cells, at least about 6 x 10 7 Individual cells, at least about 6 x 10 7 Individual cells, 8×10 7 Individual cells, at least about 9 x 10 7 Individual cells, at least about 1 x 10 8 Individual cells, at least about 2 x 10 8 Individual cells, at least about 3 x 10 8 Individual cells, at least about 4 x 10 8Individual cells, at least about 5 x 10 8 Individual cells, at least about 6 x 10 8 Individual cells, at least about 6 x 10 8 Individual cells, at least about 8 x 10 8 Individual cells, at least about 9 x 10 8 Individual cells, at least about 1 x 10 9 Individual cells, at least about 2 x 10 9 Individual cells, at least about 3 x 10 9 Individual cells, at least about 4 x 10 9 Individual cells, at least about 5 x 10 9 Individual cells, at least about 6 x 10 9 Individual cells, 8×10 9 Individual cells, at least about 9 x 10 9 Individual cells, at least about 1 x 10 10 Individual cells, at least about 2 x 10 10 Individual cells, at least about 3 x 10 10 Individual cells, at least about 4 x 10 10 Individual cells, at least about 5 x 10 10 Individual cells, at least about 6 x 10 10 Individual cells, at least ab to about 9×10 10 Individual cells, at least about 9 x 10 10 Individual cells, at least about 1 x 10 11 Individual cells, at least about 2 x 10 11 Individual cells, at least about 3 x 10 11 Individual cells, at least about 4 x 10 11 Individual cells, at least about 5 x 10 11 Individual cells, at least about 8 x 10 11 Individual cells, at least about 9 x 10 11 cells or at least about 1 x 10 12 For example, the kit may contain approximately 5×10 10 In another embodiment, the kit may contain 3×10 cells. 6 The cells can contain approximately 5×10 10 The cells can be expanded and administered to a subject.
[0206] In some embodiments, the kits can include allogeneic cells. In some embodiments, the kits can include cells that can include genomic modifications. In some embodiments, the kits can include "off-the-shelf" cells. In some embodiments, the kits can include cells that can be expanded for clinical use. In some cases, the kits can include content for research purposes.
[0207] In some embodiments, the instructions include at least one of the following: description of the therapeutic agent; dosage regimen and administration for treating or preventing a tumor or a symptom thereof; precautions, warnings, contraindications, excessive information, side effects, animal pharmacology, clinical studies, and / or literature references. The instructions can be printed directly on the container (if present), or directly on a tag on the container, or printed on a paper, pamphlet, card, or file provided separately within or on the container. In some embodiments, the instructions provide a method of administering the immune response cells of the present invention to treat or prevent a tumor. In some cases, the instructions provided a method of administering the immune response cells of the present invention before, after, or simultaneously with administration of a chemotherapeutic agent.
[0208] In another aspect, the present disclosure provides a method for inducing cell death comprising contacting the cell with an antigen binding unit described herein, a chimeric antigen receptor described herein, a composition described herein, or a host cell described herein. In some embodiments, the contacting is in vitro contacting. In some embodiments, the contacting is in vivo contacting.
[0209] In some embodiments, the cell is a tumor cell. In some embodiments, the cell is a cell of a solid tumor. In some embodiments, the cell is a cell of a cancer or tumor described herein. Examples of such cells include leukemia (e.g., acute leukemia, acute lymphocytic leukemia, acute myeloid leukemia, acute myeloid leukemia, acute promyelocytic leukemia, acute granulocytic-monocytic leukemia, acute monocytic leukemia, acute leukemia, chronic leukemia, chronic granulocytic leukemia, chronic lymphocytic leukemia, polycythemia vera) cells, lymphoma (Hodgkin's disease, non-Hodgkin's disease) cells, primary macroglobulinemia cells, heavy chain disease cells, sarcoma and cancer cells (e.g., fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, chordoma, endothelial sarcoma, lymphangiosarcoma, angiosarcoma, lymphangioendothelial sarcoma, synovial vioma, mesothelioma, Ewing's tumor, hepatoma, endothelial sarcoma, hepatoma ... Solid tumors such as leiomyosarcoma, rhabdomyosarcoma, colon cancer, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, carcinoma, bronchial carcinoma, medullary carcinoma, renal cell carcinoma, liver cancer, cholangiocarcinoma, choriocarcinoma, epithelial tumor, embryonal carcinoma, neoblastoma, cervical cancer, uterine cancer, testicular cancer, lung cancer, small cell lung carcinoma, bladder cancer, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pineal tumor, hemangioblastoma, acoustic neuroma, oligodendroglioma, neurinoma, meningioma, melanoma, neuroblastoma, retinoblastoma), esophageal cancer cells, gallbladder cancer cells, kidney cancer cells, multiple myeloma cells, etc., are not limited to these. In some embodiments, the cells are gastric cancer cells, esophageal cancer cells, colon cancer cells, pancreatic cancer cells, nephroblastoma cells, lung cancer cells, ovarian cancer cells, colon cancer cells, rectal cancer cells, hepatic cancer cells, head and neck cancer cells, chronic myeloid leukemia cells, and gallbladder cancer cells.
[0210] In another aspect, the description provides a method of treating a tumor in an individual in need of treatment, the method comprising administering to the individual an effective amount of an antigen binding unit, chimeric antigen receptor, composition, vector or host cell described herein. In some embodiments, the tumor includes, but is not limited to, a tumor selected from the group consisting of bladder, bone, brain, breast, cartilage, glial cells, esophagus, fallopian tube, gallbladder, heart, intestine, kidney, liver, lung, lymph node, nervous tissue, ovary, pancreas, prostate, skeletal muscle, skin, spinal cord, spleen, stomach, testis, thymus, thyroid, trachea, urethra, ureter, urethra, uterus, and vaginal organs. In certain embodiments, the tumor is selected from the group consisting of leukemia (e.g., acute leukemia, acute lymphocytic leukemia, acute myeloid leukemia, acute myeloid leukemia, acute promyelocytic leukemia, acute granulocytic-monocytic leukemia, acute monocytic leukemia, acute leukemia, chronic leukemia, chronic granulocytic leukemia, chronic lymphocytic leukemia, polycythemia vera), lymphoma (Hodgkin's disease, non-Hodgkin's disease), primary macroglobulinemia, heavy chain disease, sarcoma, and carcinoma (e.g., fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, chordoma, endothelial sarcoma, lymphangiosarcoma, angiosarcoma, lymphangioendothelial sarcoma, synovial vioma, mesothelioma, Ewing's tumor, Solid tumors such as leiomyosarcoma, rhabdomyosarcoma, colon cancer, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, carcinoma, bronchial carcinoma, medullary carcinoma, renal cell carcinoma, liver cancer, cholangiocarcinoma, choriocarcinoma, epithelial tumors, embryonal carcinoma, neoblastoma, cervical cancer, uterine cancer, testicular cancer, lung cancer, small cell lung cancer, bladder cancer, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pineal tumor, hemangioblastoma, acoustic neuroma, oligodendroglioma, neurinoma, meningioma, melanoma, neuroblastoma, retinoblastoma), esophageal cancer, gallbladder cancer, kidney cancer, multiple myeloma, and the like. In some embodiments, the tumor is gastric cancer, esophageal cancer, colon cancer, pancreatic cancer, nephroblastoma, lung cancer, ovarian cancer, colon cancer, rectal cancer, liver cancer, head and neck cancer, chronic myeloid leukemia, or gallbladder cancer.
[0211] In some embodiments, immunoreactive cells can be administered to a subject, where the immunoreactive cells that can be administered can be about 1 to about 35 days old. For example, the administered cells can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or up to about 40 days old. The age of the CAR immunoreactive cells can be calculated from the time of stimulation. The age of the CAR immunoreactive cells can be calculated from the time of stimulation. The age of the immunoreactive cells can be calculated from the time of blood collection. The age of the immunoreactive cells can be calculated from the time of transduction. In some embodiments, the immunoreactive cells that can be administered to a subject are about 10 days old to about 14 days old or about 20 days old. In certain embodiments, the "age" of immunoreactive cells can be determined by telomere length. For example, "young" immunoreactive cells can have longer telomere lengths than "exhausted" or "old" immunoreactive cells. Without being bound to a particular theory, it is believed that immunoreactive cells lose an estimated telomere length of about 0.8 kb per week in culture, and that young immunoreactive cell cultures have telomeres that are about 1.4 kb longer than about 44-day-old immunoreactive cells. Without being bound to a particular theory, it is believed that longer telomere lengths can be associated with objective clinical responses in patients and durability of cells in vivo.
[0212] Before, after, and / or during transplantation, the cells (e.g., artificial cells or engineered primary T cells) may be functional. For example, the transplanted cells may function for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 60, 70, 80, 90, or 100 days after transplantation. The transplanted cells may function for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months after transplantation. The transplanted cells can function for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, or 30 years after transplantation. In some embodiments, the transplanted cells can function for the life of the recipient.
[0213] Furthermore, transplanted cells are able to function at 100% of their normal expected function. Transplanted cells are able to function at approximately 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 109%, 109%, 108%, 109%, 109%, 102%, 104%, 105 2%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or up to about 100% functional.
[0214] The transplanted cells can also function at 100% or more of their normal expected function. For example, the transplanted cells can cause the cells to function at about 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 250%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1000% or up to about 5000% of their normal function.
[0215] The transplantation can be performed by any type of transplantation. The local area can include, but is not limited to, the subcapsular space of the liver, the subcapsular space of the spleen, the subcapsular space of the kidney, the retina, the gastric or intestinal submucosa, the vascular segments of the small intestine, the venous capsule, the testis, the brain, the spleen, or the cornea. For example, the transplantation can be a subcapsular transplantation. The transplantation can be an intramuscular transplantation. The transplantation can be a portal vein transplantation.
[0216] Transplant rejection can be improved after using the immune response cell treatment of the present invention compared to when one or more wild-type cells are transplanted into the recipient. For example, the transplant rejection can be a hyperacute rejection. The transplant rejection can be an acute rejection. Other types of rejection can include chronic rejection. The transplant rejection can be a cell-mediated rejection or a T cell-mediated rejection. The transplant rejection can be a natural killer cell-mediated mediated reaction.
[0217] Improving transplantation can refer to reducing hyperacute rejection and can include reducing, alleviating or reducing side effects or symptoms. Transplantation can refer to adoptive transfer of a cellular product.
[0218] Another phenomenon of successful transplantation may be the number of days that the recipient does not require immunosuppressive treatment. For example, after providing the immune response cells of the present invention, the recipient may not require immunosuppressive treatment for at least about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days or more. This may indicate successful transplantation. This may also indicate the absence of rejection of the transplanted cells, tissues and / or organs.
[0219] In some cases, the recipient does not require immunosuppressive treatment for at least 1 day. The recipient may not require immunosuppressive treatment for at least 7 days. The recipient may not require immunosuppressive treatment for at least 14 days. The recipient may not require immunosuppressive treatment for at least 21 days. The recipient may not require immunosuppressive treatment for at least 28 days. The recipient may not require immunosuppressive treatment for at least 60 days. Additionally, the recipient may not require immunosuppressive treatment for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more years.
[0220] Another phenomenon of successful transplantation can be a reduction in the number of days that the recipient requires immunosuppressive therapy. For example, following the treatments provided herein, the recipient can require reduced immunosuppressive therapy for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more days. This can indicate a successful transplantation. This can also indicate that there is no or very little rejection of the transplanted cells, tissues and / or organs.
[0221] For example, the recipient may require reduced immunosuppressive therapy for at least 1 day. The recipient may also require reduced immunosuppressive therapy for at least 7 days. The recipient may require reduced immunosuppressive therapy for at least 14 days. The recipient may require reduced immunosuppressive therapy for at least 21 days. The recipient may require reduced immunosuppressive therapy for at least 28 days. The recipient may require reduced immunosuppressive therapy for at least 60 days. Furthermore, the recipient may require reduced immunosuppressive therapy for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more years.
[0222] Reduced immunosuppressive therapy can mean less immunosuppressive therapy as compared to that required when transplanting one or more wild-type cells into a recipient.
[0223] Immunosuppressive therapy can include any therapy that inhibits the immune system. Immunosuppressive therapy can help alleviate, reduce or eliminate transplant rejection in a patient. For example, immunosuppressants can be used before, during and / or after transplantation and include MMF (Mycophenolate mofetil (Cellcept)), ATG (Anti-Thymocyte Globulin), Anti-CD154 (CD4OL), Anti-TNF-α (Anti-TNF-α ... ), anti-CD40 (2C10), immunosuppressants, anti-IL-6R antibodies (tocilizumab, Actemra), anti-IL-6 antibodies (sarilumab, olokizumab), CTLA4-Ig (Abatacept / Orencia), anti- IL-6 antibody (ASKP1240, CCFZ533X2201), amphetamine (Campath), anti-CD20 (rituximab), bevacizumab (LEA29Y), These include sirolimus (Rapimune), everolimus, tacrolimus (Prograf), daclizumab (Ze-napax), basiliximab (Similect), infliximab (Remicade), cyclosporin, digoxigenin, soluble complement receptor 1, cobra venom, anti-C5 antibody (eculizumab / Soliris), methylprednisolone, FTY720, everolimus, leflunomide, anti-IL-2R-Ab, rapamycin, anti-CXCR3 antibody, anti-ICOS antibody, anti-OX40 antibody and CD122 antibody. It should be noted that one or more immunosuppressants / drugs can be used together or sequentially. One or more immunosuppressants / drug treatments can be used to induce or maintain the treatment. The same or different drugs can be used in the induction and maintenance steps.In some cases, daclizumab (Zenapax) can be used for induction therapy, and tacrolimus (Prograf) and rapamycin (Rapimune) can be used for maintenance therapy. Non-drug approaches can be used to achieve immunosuppression, including, but not limited to, systemic probing, thymic probing, and total and / or partial splenectomy. These techniques can also be used in combination with one or more immunosuppressive agents.
[0224] In some embodiments, the antigen binding units, chimeric antigen receptors, compositions, vectors or host cells described herein can be administered in combination with another therapeutic agent, which in some embodiments is a chemotherapeutic agent, such as those described in US20140271820. Chemotherapeutic agents that may be applied in combination with the immune response cells of the present invention include mitotic inhibitors (vinca alkaloids) including vincristine, vinblastine, vindesine, novibin (TM) (vinorelbine, 5'-dihydrohydrogen sulfide); topoisomerase I inhibitors such as camptosarTM (irinotecan HCL), HycamtinTM (topotecan HCL) and other compounds derived from camptosin and its analogs; podophyllotoxin derivatives such as etoforide, teniposide, midozozo; alkylating agents cisplatin, cyclophosphamide, nitrogen mustard, trimethylene thiophosphoramide, carmustine, busulfan, chlorambucil, briq The additional therapeutic agents include, but are not limited to, one or more of epirubicin, oxaliplatin, and 5-fluorouracil, antimetabolites including cytarabine, 5-fluorouracil, methotrexate, guanidine, azathioprine, and procarbazine, antibiotics including, but not limited to, doxorubicin, breuromycin, dactinomycin, daunorubicin, mycin mycin, mitomycin, sarcomycin C, and daunorubicin, and other therapeutic agents including, but not limited to, antitumor antibodies, dacarbazine, cytidine, amushakang, melphalan, isophosphamide, and mitoxantrone. In some embodiments, the additional therapeutic agent is selected from one or more of epirubicin, oxaliplatin, and 5-fluorouracil.
[0225] In certain embodiments, chemotherapeutic agents that can be administered in combination with the immune response cells of the present invention include, but are not limited to, anti-angiogenic agents, including anti-VEGF antibodies (including humanized and chimeric antibodies, anti-VEGF aptamers and antisense oligonucleotides), and other angiogenesis inhibitors, including angiostatin, endostatin, interferon, interferon 1 (including alpha and beta), interleukin 12, retinoic acid, tissue inhibitor of protease-1-1 and tissue inhibitor of protease-2.
[0226] Working Example Next, the present invention will be described in more detail with reference to specific examples. It should be understood that these examples are merely for the purpose of illustrating the present invention and are not intended to limit the scope of the present invention. In the following examples, experimental methods that do not specify specific conditions generally follow standard conditions such as those described in J. Sambrook et al., Molecular Cloning Experimental Procedures, 3rd Edition, Science Press, 2002, or conditions suggested by manufacturers. In the following examples of the present invention, when constructing a receptor or CAR bound to the antigen, the domain of the CD28 costimulatory signal is abbreviated as 28, CD3ζ is abbreviated as Z, and 4-1BB or CD137 is abbreviated as BB. For example, a chimeric antigen receptor constructed by using an scFv coded 8E5-2I and the domains of CD3ζ and CD28 costimulatory signal as the intracellular signal domain can be represented as 8E5-2I-28Z. The construction of CARs for different antigens is the same.
[0227] Example 1. Generation and characterization of mouse antibodies against CLD18A2 Obtain antibody fragments using standard biological methods. Briefly, use 8-week-old Balb / c mice immunized with eukaryotic expression vector of human CLD18A2 full-length sequence (NCBI Reference Sequence: nM_001002026.2). After immunization, remove the spleen of the mouse, and obtain monoclonal antibodies using conventional biological methods in the art.
[0228] Anti-CLD18A2 monoclonal antibodies were screened from single cells by flow cytometry analysis, and then initially screened by flow cytometry analysis in HEK293 cells stably expressing human CLD18A2 (HEK-CLD18A2) using the Guava easyCyte™ HT System instrument, and the binding of the antibodies to human CLD18A1 and CLD18A2 transfectants was compared again by flow cytometry. The instrument used was the Guava easyCyte™ HT System.
[0229] Through multiple hybridoma production and screening, several antibodies with relatively ideal binding properties were found. Figure 1B shows the binding of hybridoma supernatants 2B1, 3E12, 4A11 and 8E5 to human CLD18A2 and HEK293 cells stably transfected with CLD18A1 cells, as measured by flow cytometry analysis. As shown in Figure 1B, after two subclonings, most of the antibodies 2B1, 3E12, 4A11 and 8E5 subclones specifically bound to human CLD18A2 but did not bind to CLD18A1, and the average fluorescence intensity was more than 5-fold different.
[0230] Hybridoma cell lines secreting monoclonal antibodies were cultured, and total RNA was extracted from the cell pellet according to the instructions of the TRIzol® Plus RNA Purification kit (Invitrogen, 12183-555). Using the total RNA as a template, cDNA was synthesized by reverse transcription according to the instructions using the High capacity RNA to cDNA kit (Invitrogen, 4387406). Using the cDNA as a template, amplification was performed using the antibody constant region primer with the 5'-Full RACE kit (TAKARA, D315). The PCR products were separated by 1.5% agarose gel electrophoresis, and then purified to recover the DNA fragments. The results after sequencing are as follows:
[0231] TIFF0007587921000006.tif64170
[0232] The antibody sequences were compared and the results are shown in FIG. Example 2. Construction of anti-claudin-18A2 scFv_Fc fusion antibody and its transient expression in eukaryotic cells The VH and VL fragments of 2B1 and 8E5 were each introduced with the flexible amino acid GGGGSGGGSGGGGS (SEQ ID NO: 93) as a linker to construct scFv, and a suitable enzyme cleavage site and protective base were introduced upstream of VH, and a suitable enzyme cleavage site and protective base were introduced downstream of VL, and the eukaryotic expression vector after enzyme cleavage was linked and inserted (see vector pH or vector pK used in CN101602808). Transient transfection was performed using 293fectinTM Transfection reagent (Invitrogen, 12347-019), and the supernatant was collected and cultured, affinity purified, and quantitative and qualitative analysis of the obtained antibodies was performed via SDS PAGE.
[0233] The binding of anti-claudin 18A2 scFv_Fc fusion antibody to HEK293 cells stably transfected with CLD18A2 was measured through flow cytometry analysis. Referring to Example 1, the experimental data was analyzed with GraphPad Prism using a Guava easyCyteTM HTSystem instrument to obtain EC50. Figure 3 shows the relative binding affinity of monoclonal antibodies 2B1 and 8E5 ScFv partially fused with human IgG1 Fc to HEK293 cells stably transfected with human CLD18A2. It can be seen that the EC50 value of 2B1 is 3.56 nM and the EC50 value of 8E5 is 49.19 nM.
[0234] Example 3. Production and preparation of mutants of anti-claudin 18A2 antibodies Using bridge PCR method, site-directed mutagenesis was performed on antibody 2B1 to mutate site 52 or site 54 (N-glycosylation site) in the heavy chain of antibody 2B1 to generate two 2B1 mutants, 2B1-N52D (VH amino acid sequence: SEQ ID NO:17, nucleotide sequence: SEQ ID NO:18) and 2B1-S54A (VH amino acid sequence: SEQ ID NO:19, nucleotide sequence: SEQ ID NO:20).
[0235] The amino acid and nucleotide sequences of the light chains of 2B1-N52D and 2B1-S54A are identical to the corresponding sequences of 2B1.
[0236] Referring to Example 2, expression vectors of the ScFv_Fc forms of these two mutants were constructed, and referring to the procedures of Example 2 and Example 1, the experimental data was analyzed using GraphPad Prism on a Guava easyCyteTM HT System instrument to obtain EC50.
[0237] The results are shown in Figure 4, which shows the relative binding affinity of 2B1-N52D and 2B1-S54A ScFvs partially fused to human IgG1 Fc and then stably transfected with human CLD18A2 in HEK293 cells. It can be seen that the EC50 value of 2B1-N52D is 6.11 nM and the EC50 value of 2B1-S54A is 3.85 nM.
[0238] Example 4. Production and manufacturing of humanized antibody 2B1-S54A Combining the naming schemes of the three antibody CDR regions of Kabat, Chothia and IMGT, the sequences of six CDR regions of the antibody light chain and heavy chain were determined. The sequence similarity was compared, and the antibody with the highest similarity to 2B1-S54A was selected as the antibody template. In this embodiment, IGHV1-46*01 was selected from the IMGT data library as the antibody template for the hu2B1-S54A heavy chain. IGKV4-1*01 was used as the antibody template for the hu2B1-S54A light chain. The light chain and heavy chain CDR regions of 2B1-S54A were replaced with the CDR regions of the antibody template.
[0239] Determine the sites where the mutations are restored: (1) Compare the well-designed humanized antibody with the starting antibody to check for differences in certain amino acids in the framework region of the antibody. (2) Check whether these different amino acids support the antibody loop structure or affect the binding of the light chain and heavy chain variable region, and if so, these regions are relatively conservative regions. (3) Check whether there are any potential post-translational modification sites in some parts of the humanized antibody, such as deamidation sites (Asn-Gly), isomerization sites (Asp-Gly), surface-exposed methionine, and N-glycosylation sites (Asn-X-Ser / Thr, where X is not proline). (4) In the humanized antibody (hu2B1-S54A), the heavy chain has six potential mutation restoration sites, which are M48I, V68A, M70L, R72A, T74K, and T91S, respectively. In the humanized antibody (hu2B1-S54A), the light chain has one potential mutation restoration site, L84V.
[0240] Expression and purification of humanized antibody: (1) Based on the amino acid sequence of humanized antibody (hu2B1-S54A), a nucleotide sequence was designed and synthesized. The light chain nucleotide sequence (SEQ ID NO:62) was synthesized, and the heavy chain nucleotide sequence (SEQ ID NO:60) was synthesized. (2) The synthetic antibody nucleotide sequence including the signal peptide, antibody variable region, and constant region was inserted into a mammalian cell expression vector to construct an antibody expression vector including heavy chain and light chain, respectively, and the sequence was measured and identified.
[0241] The heavy chain amino acid sequence of hu2B1-S54A is as set forth in SEQ ID NO:59 and the nucleotide sequence is as set forth in SEQ ID NO:60. The hu2B1-S54A light chain amino acid sequence is as set forth in SEQ ID NO:61 and the nucleotide sequence is as set forth in SEQ ID NO:62. The hu2B1-S54A heavy chain variable region amino acid sequence is as set forth in SEQ ID NO:23 and the nucleotide sequence is as set forth in SEQ ID NO:24, and the light chain variable region amino acid sequence is as set forth in SEQ ID NO:21 and the nucleotide sequence is as set forth in SEQ ID NO:22.
[0242] 293F cells were transiently transfected with 293Fectin to express the same sequences as the HCDR and LCDR of hu2B1-S54A. Referring to the measurement of binding activity described in Example 2, human CLD18A2 was stably expressed in HEK293 cells (HEK-CLD18A2) using Guava easyCyte. TM The experimental data was analyzed using HTSystem instrument and GraphPad Prism to obtain EC50. The results are shown in Figure 5, which shows that after the scFv of hu2B1-S54A was partially fused with human IgG1 Fc, the relative binding affinity EC50 value with HEK293 cells stably transfected with human CLD18A2 was 18.59 nM, indicating that hu2B1-S54A also has excellent binding with HEK-CLD18A2.
[0243] Example 5. Production and optimization of humanized antibodies of monoclonal antibody 8E5 Referring to the procedure of Example 4, 8E5 was humanized, and at the same time, the N-glycosylation site of monoclonal antibody 8E5 was deleted by S62A mutation to obtain humanized antibody hu8E5 (or hu8E5-S62A). The specific method is as follows: (1) IGHV4-30*03 was selected as the antibody template for the 8E5 heavy chain, and IGKV4-1*01 was selected as the antibody template for the 8E5 light chain. The light or heavy chain CDR regions of the 8E5 antibody were replaced with the CDR regions of the antibody template. (2) The sites for restoring mutations were determined. The heavy chain of the humanized antibody (hu8E5) had six potential sites for restoring mutations, namely G27Y, G45K, L46M, I49M, V68I, V72R, and A97T. The light chain of the humanized antibody (hu8E5) had one potential site for restoring mutation, namely L84V. (3) Nucleotide sequences were designed based on the amino acid sequence of the humanized antibody hu8E5, and the light chain and heavy chain nucleotide sequences were synthesized. The heavy chain amino acid sequence of hu8E5-S62A is as set forth in SEQ ID NO:67, and the nucleotide sequence is as set forth in SEQ ID NO:68. The light chain amino acid sequence of hu8E5-S62A is as set forth in SEQ ID NO:65, and the nucleotide sequence is as set forth in SEQ ID NO:66. The heavy chain variable region amino acid sequence of hu8E5-S62A is as set forth in SEQ ID NO:27, and the nucleotide sequence is as set forth in SEQ ID NO:28, the light chain variable region amino acid sequence of hu8E5-S62A is as set forth in SEQ ID NO:25, and the nucleotide sequence is as set forth in SEQ ID NO:26, the HCDR2 of hu8E5-S62A is different from 8E5, the sequence of which is set forth in SEQ ID NO:85, and the other HCDRs and LCDRs are the same as 8E5. (4) The synthetic antibody nucleotide sequence including the signal peptide, the variable region, and the constant region of the antibody was inserted into a mammalian cell expression vector to construct an antibody expression vector including heavy and light chains, and the sequence was measured and identified. The antibody was expressed by transiently transfecting 293F cells with 293Fectin. (5) Binding activity was measured using Guava easyCyte in HEK293 cells stably expressing human CLD18A2 (HEK-CLD18A2). TMThe experimental data was analyzed with GraphPad Prism using the HTSystem instrument, and the results were as shown in Figure 6, which showed that the relative binding affinity of hu8E5 scFv to HEK293 cells stably expressing human CLD18A2 was 107 nM after it was partially fused with human IgG1 Fc.
[0244] A 3D model of hu8E5 was established with Discovery studio software, and potential aggregation sites were analyzed, and it was found that proline at positions 12 and 93 of the heavy chain was prone to antibody aggregation and affected the stability of the antibody. Through point mutation analysis, these two sites were mutated to I, making the antibody more stable. Molecular sieving results showed that after these two sites were mutated to I (hu8E5-2I), the proportion of monomeric form in the scFv_Fc fusion antibody was improved from the original 74% (hu8E5) to 87% (hu8E5-2I).
[0245] The heavy chain amino acid sequence of hu8E5-2I is as set forth in SEQ ID NO:63, and the nucleotide sequence is as set forth in SEQ ID NO:64. The hu8E5-2I light chain amino acid sequence is as set forth in SEQ ID NO:65, and the nucleotide sequence is as set forth in SEQ ID NO:66. The HCDR2 in hu8E5-2I is different from 8E5, but is the same as hu8E5, the sequence of which is as set forth in SEQ ID NO:85, and the other HCDRs and LCDRs are the same as 8E5.
[0246] Refer to the construction of mutant hu8E5-2I of humanized antibody hu8E5 described in Example 3. Human CLD18A2 is stably expressed in HEK293 cells (HEK-CLD18A2), and the experimental data is analyzed by GraphPad Prism using Guava easyCyteTM HT System instrument, and the results are shown in Figure 7, which shows the relative binding affinity of hu8E5-2I scFv partially fused with human IgG1 Fc and then with HEK293 cells stably transfected with human CLD18A2, and its EC50 value is 9.22 nM. Mutant hu8E5-2I has 5-fold improved affinity compared to parent antibody 8E5.
[0247] Example 6. In vitro and in vivo functional studies of humanized antibodies hu2B1-S54A and hu8E5-2I According to standard methods known to those skilled in the art, humanized antibody hu2B1-S54A (light chain sequence: SEQ ID NO: 62, heavy chain sequence: SEQ ID NO: 60); humanized antibody hu8E5-2I (light chain sequence: SEQ ID NO: 66, heavy chain sequence: SEQ ID NO: 64) were cloned into eukaryotic expression vectors. 293fectin™ Transfection reagent (Invitrogen, 12347-019) was used to transiently transfect 293F cells in logarithmic growth phase, and the culture supernatant was collected and affinity purified. The obtained antibodies were quantitatively and qualitatively analyzed by SDS PAGE. The eukaryotic expression vector used was Vector pH or Vector pK used in CN101602808B.
[0248] 1. Complement composition and cytotoxicity (CDC) Blood was collected from healthy volunteers and centrifuged to produce serum. A CCK-8 Cell Proliferation-Toxicity Detection Kit (Dojindo, #CK04) was used. HEK293 cells stably transfected with CLD18A2 or CLD18A1 were used as target cells. The cells were washed twice and resuspended in complete medium at a density of 1×105 cells / ml. 100 μl per well was seeded into a 96-well culture plate and cultured overnight at 37°C. On the second day, antibodies were added to each well at a concentration of 20 μg / ml. Incubated at 37°C for 30 minutes. Then, serum was added to a final concentration of 10% and incubated at 37°C for 1.5 hours. 10 μl of CCK-8 solution was added to each well and incubated at 37°C for 3.5 hours (adjusted as necessary), and the absorbance at 450 nm was measured using a microplate reader. The experiment was divided into six groups with duplicate wells, and the specific groups are as follows:
[0249] TIFF0007587921000007.tif140170
[0250] The percent dissolution is calculated as follows: Percent lysis = (cell control wells - experimental wells) / cell control wells - (cell control wells - antibody control wells) / cell control wells. Figure 8A compares the CDC results of humanized antibodies hu2B1-S54A, hu8E5-2I, and chimeric antibody ch-163E12 on HEK293 cells transfected with CLD18A2. The results show that when the antibody concentration is 20 μg / ml, the CDC efficiencies of hu2B1-S54A and hu8E5-2I on HEK293-CLD18A2 are 79.88% and 82.65%, respectively, while the CDC efficiency of ch-163E12 is lower than 55% under the same reaction conditions. Figure 8B shows the results of CDC comparing humanized antibodies hu2B1-S54A, hu8E5-2I, and chimeric antibody ch-163E12 with HEK293 cells transfected with CLD18A1. The experimental results showed that ch-163E12 had a certain killing effect on cells expressing 18A1, while hu2B1-S54A and hu8E5-2I had no killing effect on cells expressing 18A1.
[0251] 2. Antibody-dependent cytotoxicity (ADCC) activity The ADCC activity of the humanized claudin 18A2 antibody was measured by measuring lactate dehydrogenase (LDH) release using the cytoTox 96 non-radioactive cytotoxicity assay kit (Promega, Madison, USA). Human peripheral blood mononuclear cells (PBMCs) were purified from citrated whole blood by standard Ficoll-paque separation and resuspended in complete medium (RPMI-1640 medium (Gibco) containing 10% fetal bovine serum (FBS, Gibco) at a density of 8 × 10 6 HEK293 cells stably transfected with CLD18A2 were used as target cells. Cells were washed twice and diluted with 2 × 10 5 PBMCs were incubated with antibody at a final concentration of 20 μg / ml for 30 min at 37°C, after which 50 μl of antibody and 50 μl of effector cells were mixed with target cells (total 1 × 10 4After incubation at 37°C for 4 hours, the cells were centrifuged and 50 μl samples of cell-free supernatant were collected and transferred to flat-bottom 96-well plates for measurement. Percent lysis was calculated as follows: (sample release-target spontaneous release-effector cell spontaneous release) / (maximum release-target spontaneous release)*100, where target spontaneous release includes only the fluorescence of the wells with target cells, effector cell spontaneous release includes the spontaneous fluorescence of the wells with effector cells, and maximum release includes the fluorescence of the wells with cells treated with lysis buffer.
[0252] 9 compares the ADCC results of humanized antibodies hu2B1-S54A and hu8E5-2I and known chimeric antibodies ch-163E12 and ch-175D10 (see CN103509110A). The experimental results show that the ADCC effects of human antibodies hu2B1-S54A and hu8E5-2I are significantly superior to those of ch-175D10 and ch-163E12 when the antibody concentration is 20 μg / ml and the multiplicity of infection is 50:1, 20:1, and 10:1, and the ADCC effects against HEK293-CLD18A2 are 62.84% and 72.88%, respectively, when the multiplicity of infection is 50:1. However, under the same conditions, the ADCC effects of ch-163E12 and ch-175D10 on HEK293-CLD18A2 were only 33.39% and 43.74%, respectively, indicating that the antibody of the present invention has a significantly superior destructive effect than ch-163E12 and ch-175D10.
[0253] 3. In vivo experiments in mice Establishment of gastric cancer PDX model: Tumors of approximately 3 mm x 3 mm x 3 mm in size were inoculated subcutaneously into the right armpit of BALB / c nude mice. The tumor cell inoculation date was recorded as D0, and the tumor volume was measured on D27 after tumor inoculation and randomly divided into 5 groups. The specific groups were as follows: (1) PBS (phosphate buffer), control group, (2) hu8E5-2I antibody treatment group (40 mg / kg), (3) EOF treatment group (E: epirubicin: 1.25 mg / kg, O: oxaliplatin: 3.25 mg / kg, F: 5-fluorouracil: 56.25 mg / kg) + PBS, (4) hu8E5-2I antibody (40 mg / kg) + EOF treatment group (1.25 mg / kg epirubicin + 3.25 mg / kg oxaliplatin + 56.25 mg / kg 5-fluorouracil), (5) ch175D10 antibody (40 mg / kg) + EOF treatment group (1.25 mg / kg epirubicin + 3.25 mg / kg oxaliplatin + 56.25 mg / kg 5-fluorouracil). Dosage: EOF was administered once a week for two consecutive weeks, and hu8E5-2I and ch175D10 antibodies were administered three times each weekly for two weeks.
[0254] The results are shown in Figure 10. On the 56th day after tumor inoculation, EOF was injected twice and antibody was injected six times, and the mice were sacrificed by cervical dislocation. Compared with the PBS control group, the tumor inhibition rates were 21.13% for the hu8E5-2I monoclonal antibody group, 47.89% for the EOF+PBS treatment group, 81.69% for the EOF+mAb hu8E5-2I treatment group, and 71.83% for the EOF+mAb 175D10 treatment group, respectively. In terms of tumor weight measurement, the EOF+mAb hu8E5-2I group was statistically different from the EOF+PBS group (P=0.033), while the EOF+mAb 175D10 treatment group was statistically different from the EOF+PBS group (P=0.097), showing no statistical difference.
[0255] Example 7. Construction of humanized antibody chimeric antigen receptor plasmid (CAR plasmid) 1. Construction of humanized antibody hu8E5 chimeric antigen receptor plasmid Using PRRLSIN-cPPT.EF-1α as a vector, lentiviral plasmids expressing second and third generation chimeric antigen receptors for the humanized antibody hu8E5, including PRRLSIN-cPPT.EF-1α-hu8E5-28Z, PRRLSIN-cPPT.EF-1α-hu8E5-BBZ and PRRLSIN-cPPT.EF-1α-hu8E5-28BBZ, were constructed.
[0256] Hu8E5-28Z mainly contains (arranged sequentially from the 5' to 3' end): the coding sequence for the CD8α signal peptide (SEQ ID NO:70), hu8E5 scFV (VH: SEQ ID NO:27, VL: SEQ ID NO:25, Linker: SEQ ID NO:93), the CD8 hinge (SEQ ID NO:72), the CD28 transmembrane domain (SEQ ID NO:74) and intracellular signaling domain (SEQ ID NO:76), and the intracellular segment of CD3, CD3ξ (SEQ ID NO:78).
[0257] hu8E5-BBZ mainly contains (arranged sequentially from the 5' end to the 3' end) coding sequences for the CD8α signal peptide (SEQ ID NO:70), hu8E5 scFV (VH: SEQ ID NO:27, VL: SEQ ID NO:25, Linker: SEQ ID NO:93), CD8 hinge (SEQ ID NO:72) and CD8 transmembrane domain (SEQ ID NO:80), the intracellular segment transduction domain of CD137 (SEQ ID NO:82) and CD3ξ (SEQ ID NO:78).
[0258] hu8E5-BBZ mainly contains (arranged sequentially from the 5' end to the 3' end) coding sequences for the CD8α signal peptide (SEQ ID NO:70), hu8E5-scFV, CD8 hinge (SEQ ID NO:72), CD8 transmembrane domain (SEQ ID NO:74) and intracellular segment (SEQ ID NO:76), the intracellular segment transduction domain of CD137 (SEQ ID NO:82), and CD3ξ (SEQ ID NO:78).
[0259] 2. Construction of humanized antibody hu8E5-2I chimeric antigen receptor plasmid Using PRRLSIN-cPPT.EF-1α as a vector, the lentiviral plasmid PRRLSIN-cPPT.EF-1α-hu8E5-2I-28Z expressing the second-generation chimeric antigen receptor of the humanized antibody hu8E5-2I was constructed.
[0260] hu8E5-2I-28Z mainly contains (arranged sequentially from the 5' end to the 3' end): coding sequences for the CD8α signal peptide (SEQ ID NO:70), hu8E5-2I scFV (VH: SEQ ID NO:29, VL: SEQ ID NO:25, Linker: SEQ ID NO:93), CD8 hinge (SEQ ID NO:72), CD28 transmembrane domain (SEQ ID NO:74) and intracellular signaling domain (SEQ ID NO:76), and the intracellular signaling domain of CD3, CD3ξ (SEQ ID NO:78).
[0261] 3. Construction of humanized antibody hu2B1-S54A chimeric antigen receptor plasmid Using PRRLSIN-cPPT.EF-1α as a vector, the lentiviral plasmid PRRLSIN-cPPT.EF-1α-hu2B1-S54A-28Z expressing the second-generation chimeric antigen receptor for the humanized antibody hu2B1-S54A was constructed.
[0262] hu2B1-S54A-28Z mainly contains (arranged sequentially from the 5' to 3' end): coding sequences for the CD8α signal peptide (SEQ ID NO:70), hu2B1-S54A scFV (VH: SEQ ID NO:23; VL: SEQ ID NO:21; Linker: SEQ ID NO:93), CD8 hinge (SEQ ID NO:72), CD28 transmembrane domain (SEQ ID NO:74) and intracellular domain (SEQ ID NO:76), and the intracellular segment of CD3, CD3Z (SEQ ID NO:78).
[0263] Example 8. Lentiviral packaging and titration 5×10 6 293T cells that had been cultured for 6 to 10 generations at a virus density of 1000 ng / mL were inoculated into a 10 cm culture dish and cultured overnight at 37°C and 5% CO2 for transfection. The medium was DMEM containing 10% fetal bovine serum (Gibico).
[0264] The target gene plasmid PRRLSIN-cPPT.EF-1α-EGFP (Mock) and 5.4 μg of different CAR plasmids prepared in Example 9, 6.2 μg of packaging plasmids pRsv-REV, 6.2 μg of RRE-PMDLg, and 2.4 μg of Vsvg were placed in 800 μL of black DMEM culture medium, and 60 μg of PEI (1 μg / μl) was dissolved in 800 μl of serum-free DMEM culture medium, mixed uniformly, and incubated at room temperature for 5 minutes.
[0265] The plasmid mixture is added to the PEI mixture and mixed evenly. It is incubated at room temperature for 20 minutes to form a transfection complex. 1.6 ml of the transfection complex is dropped into a 10 cm culture dish containing 11 ml of DMEM medium. After 4 to 5 hours, the cultured 293T cells are replaced with 10% FBS DMEM medium and incubated at 37°C for 72 hours. The virus supernatant is collected, concentrated, and the titer is measured. The cell number with a positive rate of 5 to 20% is preferable. The titer (U / mL) is calculated as cell number x positive rate / virus volume.
[0266] After concentration, the virus titers were: hu8E5-28Z:2.3×10 7 U / ml, hu8E5-BBZ:6.65×10 7 / ml, hu8E5-28BBZ:6.67×10 7 / ml, hu8E5-2I-28Z:1.54×10 8 U / ml, hu2B1-S54A-28Z:1.14×10 8U / ml.
[0267] Example 9. Measurement of cytotoxicity of lentiviral-transduced T lymphocytes and CAR-T cells 1. Lentivirus-infected T lymphocytes (1) Approximately 1×10 6 The cells were cultured in lymphocyte culture medium at a density of 100 / mL, and magnetic beads:cell ratio was added at 1:1. At the same time, magnetic beads coated with anti-CD3 and CD28 antibodies (Invitrogen) and recombinant human IL-2 at a final concentration of 300 U / mL were added and cultured for 48 hours. (2) Coating a 24-well plate with Retronectin: Add 380 μl of 5 μg / ml retronectin solution (PBS) to each well, incubate at 4°C overnight, discard the retronectin solution (PBS) from the 24-well plate, and wash twice with 1 ml of PBS. (3) Cells were seeded into retronectin-coated 24-well plates, with the number of cells in each well being 3 × 10 5 The culture liquid volume was 600 μl, and the concentrated lentivirus was added to PBMCs cells based on MOI=10. The cells were centrifuged at 32° C. for 40 minutes and then transferred to a cell incubator. (4) Amplification culture: After infection, the cells were cultured at 5 × 10 5 Lymphocyte cultures were passaged at a density of 100 / mL and lymphocyte culture medium was supplemented with recombinant human IL-2 to a final concentration of 300 U / mL.
[0268] 2. Expression of chimeric antigen receptors on T lymphocytes (1) Lentivirus-infected T lymphocytes were cultured at 1 × 10 6 The T cells were collected, divided into two equal portions and placed in 2 ml centrifuge tubes, centrifuged at 4° C. and 5000 rpm for 5 minutes, the supernatant was discarded, and the cells were washed twice with PBS. (2) 50 μl of PE-SA antibody (diluted 1:200) was added to the control group cells, incubated on ice for 45 minutes, washed twice with PBS (2% NBS), and resuspended. The detection group cells + 50 μl of biotin-Goat anti-human IgG, F, (ab')2 antibody (diluted 1:50) were added to the control group cells, incubated on ice for 45 minutes, and washed twice with PBS (2% NBS). (3) 50 μl of PE-SA antibody (diluted 1:200) was added and incubated on ice for 45 minutes. 2 ml of PBS (2% NBS) was added to resuspend the cells. After centrifugation, the supernatant was discarded. (4) The proportion of CAR-positive T cells was detected by flow cytometry. The infection-positive rates of the three CAR T cells, hu8E5-28Z, hu8E5-BBZ, and hu8E5-28BBZ, and the mock control cells, were 52.1%, 47.8%, 44.6%, and 71.7%, respectively.
[0269] 3. Measurement of cytotoxicity targeting CLD18A2 CAR T cells (1) Target cells: 75 μL of 2 × 10 5 293T-A1 cells, 293T-A2 cells, gastric cancer cell lines AGS, AGS-A2, gastric cancer cell lines BGC-823, and BGC-823-A2 cells were inoculated at 100 / mL. Gastric cancer cell lines AGS and BGC-823 were purchased from the ATCC cell library, and 293T-A1 cells, 293T-A2 cells, AGS-A2, and BGC-823-A2 cells were constructed using cell lines based on CN101602808B, where 293T-A2 cells, AGS-A2, and BGC-823-A2 cells are CLD18A2 positive cells, and the rest are CLD18A2 negative cells. (2) Effector cells: T-Mock and CAR T cells expressing different chimeric antigen receptors were included based on effector:target ratios of 3:1, 1:1, or 1:3. (3) For each group, four duplicate wells were set up, and the average value of the four duplicate wells was calculated. The detection time was 18 hours. Here, the experimental groups and control groups are as follows: Each experimental group: each target cell + CAR T expressing a different chimeric antigen receptor, Control group 1: maximum release of LDH from target cells; Control group 2: spontaneous release of LDH from target cells; Control group 3: spontaneous release of LDH from effector cells; (4) Detection method: CytoTox96 non-radioactive cytotoxicity detection kit (Promega) was used. Lactate dehydrogenase (LDH) was quantitatively measured by CytoTox96 (registered trademark) detection. Specifically, the manual for the CytoTox 96 non-radioactive cytotoxicity detection kit was referred to. (5) Cytotoxicity calculation formula: TIFF0007587921000008.tif19170
[0270] The cell killing results of different efficacy:target ratios are shown in Figures 11 and 12. The results show that the CAR-T products have excellent killing effects on 293T-A2, AGS-A2 and BGC-823-A2 cells, which are positive for CLD18A2 expression. Here, hu8E5-28Z and hu8E5-2I-28Z cells can kill more than 60% of AGS-A2 cells when the efficacy:target ratio is 3:1, and the killing of BGC-823-A2 cells can be more than 90%. In addition, the results also show that the killing effect of each CAR T cell (Hu2B1-S54A-28Z and others) on cells negative for CLD18A2 expression is not clear.
[0271] Example 10. In vivo activity of CLD18A2 CAR-T cells We observed antitumor therapy experiments of untransfected T cells (UTD), hu8E5-2I-28Z T cells, against tumors subcutaneously implanted in a gastric cancer PDX model. 1) Establishment of gastric cancer PDX model: Gastric cancer PDX tumors measuring approximately 2 × 2 × 2 mm were inoculated subcutaneously into the right armpit of 6-8 week-old female NOD / SCID mice, and the day of tumor cell inoculation was designated as D0. 2) Division of experimental groups: On day 15 after tumor inoculation, NOD-SCID mice were randomly divided into three groups, each with 7 mice, into a non-transfected T cell group and a hu8E5-2I-28Z T cell group. 3) Adoptive transfer of T cells: Tumor volume 30 mm 3 In the case of 7 CAR-T cells were injected via the tail vein, and the non-transfected T cell group served as the control group. The growth of gastric cancer PDX subcutaneously transplanted tumors was observed and measured. The experimental results are shown in Figures 13A and 13B. On the 32nd day after CAR T injection, the mice were sacrificed by cervical dislocation. Compared with the UTD group, the hu8E5-2I-28Z group had a significant tumor inhibition effect, with an inhibition rate of 79.2%. In terms of tumor weight, the hu8E5-2I-28Z treatment group was statistically different from the UTD group, with P=0.01.
[0272] Example 11. In vitro cytokine release induction test of CLD18A2 CAR-T cells To verify that the constructed hu8E5-28Z, hu8E5-2I-28Z T cells could be effectively activated under the stimulation of target cells, we detected the secretion of cytokines from hu8E5-28Z, hu8E5-2I-28Z T cells after co-incubation with target cells. At the same time, cytokines released by T cells (Mock), hu8E5-28Z and hu8E5-2I-28Z T cells after incubation were detected. After infection with lentivirus, the two T cells were collected in good growth state within 1 to 2 weeks, and 5 × 10 4 / 200 µL (number of positive cells) into 24-well plates, depending on the efficacy:target ratio of 1:1, 5 × 10 4Target cells were inoculated at 200μL per well per 24 wells. The target cells included 293T-A1, 293T-A2, AGS, AGS-A2, BGC-823 and BGC-823-A2 cells. After 24 hours of co-culture, the supernatants were collected. The sandwich ELISA method was used to detect IL2, IFN-γ and TNF-α released during the co-culture of CAR T lymphocytes and target cells in the supernatants.
[0273] The experimental results are shown in Figure 14. The results show that when hu8E5-28Z and hu8E5-2I-28Z are incubated with 293T-A2, AGS-A2 and BGC-823-A2 cells that are positive for CLD18A2 expression, they can activate the secretion of IL-2, IFN-γ and TNF-α cytokines, while the Mock control group cannot activate the secretion of the cytokines, and there is a significant difference between the two. When hu8E5-2I-28Z is incubated with 293T-A1, AGS and BGC-823 cells that are negative for CLD18A2 expression, they cannot activate the secretion of IL-2, IFN-γ and TNF-α cytokines, and the Mock control group cannot activate the secretion of the cytokines. The experimental results show that cells that are positive for CLD18A2 expression can effectively activate hu8E5-2I-28Z CAR T cells.
[0274] Example 12. In vivo killing activity of CLD18A2 CAR-T cells Measurement of antitumor therapeutic experiments of non-transfected T cells (Mock), hu8E5-28Z and hu8E5-2I-28Z T cells against tumors subcutaneously implanted with BGC-823-A2 cells 1) Inoculation of BGC-823-A2 subcutaneous tumor: BGC-823-A2 cells in the logarithmic growth phase and in good condition were harvested and diluted to a density of 2.5 × 10 in saline. 7 / mL, and 200 μL (5 × 10 6 A volume of the cell suspension (100 mg / mouse) was injected subcutaneously into the right armpit of the mice. The day of tumor cell inoculation was recorded as day 0. 2) Division of experimental groups: On the 11th day after tumor inoculation, the volume of the BGC-823-A2-implanted tumor was measured, and the NOD-SCID mice were randomly divided into three groups, each with six mice: the non-transfected T cell group, the hu8E5-28Z T cell group, and the hu8E5-2I-28Z T cell group. 3) Adoptive transfer of T cells: Tumor volume is 100-150 mm 3 (day 11), 100 mg / kg cyclophosphamide was injected intraperitoneally, and 1 × 10 7 CAR-T cells (Mock cells, hu8E5-28Z T cells, or hu8E5-2I-28Z T cells) were injected via the tail vein, and the growth of subcutaneously implanted tumors was observed and measured using a non-transfected T cell group (Mock group) as a control group.
[0275] The results of the animal experiment are shown in Figure 15. The results show that on the 17th day of treatment with hu8E5-28Z and hu8E5-2I-28Z CAR T cells, the tumor inhibition rates for BGC-823-A2 transplanted tumors were 81.3% and 89.2%, respectively, and the hu8E5-28Z and hu8E5-2I-28Z treatment groups for BGC-823-A2 transplanted tumors were significantly different in terms of therapeutic effect than the Mock control group. After 17 days of treatment, the mice were sacrificed and the transplanted tumors were taken and weighed. The average tumor weights of the BGC-823-A2 transplanted tumors in the hu8E5-28Z and hu8E5-2I-28Z treatment groups were 0.1g and 0.06g, respectively, and the average tumor weight of the Mock control group was 0.53g, and there was a significant difference between the CAR T cell group and the Mock control group, with P values of 0.0013 and <0.0001, respectively.
[0276] Example 13: Effect of CLD18A2 CAR-T cells on tumor infiltration in vivo Referring to the animal model of BGC-823-A2 cell subcutaneously transplanted tumor established in Example 12, Mock, hu8E5-28Z, and hu8E5-2I-28Z cells were reused for 17 days, and then tumor tissues were collected and CD3+ cells were detected by histochemistry.
[0277] As shown in Figure 16, in the case of Mock T cells, infiltration of T cells was hardly observed around the tumor tissue, whereas infiltration of CD3+ T cells could be observed around the tumor tissue in the case of hu8E5-28Z and hu8E5-2I-28Z cells, with even more infiltration of T cells observed around the tumor tissue in the hu8E5-2I-28Z group.
[0278] Example 14. Production of IFN-coexpressing CAR-T cells With reference to the operations of Examples 7 to 9, construct the plasmid of hu8E5-28Z-IFNb CAR expressing IFNb cytokine based on hu8E5-28Z, construct the plasmid of hu8E5-2I-28Z-IFN CAR capable of expressing IFNb cytokine based on hu8E5-2I-28Z CAR, and obtain hu8E5-28Z-IFNb CAR T cells (also referred to as hu8E5-28Z&IFNB) and hu8E5-2I-28Z-IFN CAR T cells (also referred to as hu8E5-2I-28Z&IFNB) co-expressing IFNb through lentivirus packaging and infection. Here, hu8E5-28Z-IFNb CAR is encoded by the nucleotide sequence of SEQ ID NO:90, and hu8E5-2I-28Z-IFN CAR is encoded by the nucleotide sequence of SEQ ID NO:91.
[0279] With reference to the procedures in Example 11, an in vitro cytokine release induction test was conducted, and the results were as shown in Figure 17A, in which the presence of IFN increased the secretion of IFN-γ cytokine when hu8E5-28Z CAR T cells were incubated with target cells.
[0280] Antitumor therapy experiments were performed using untransfected T cells (UTD), hu8E5-28Z T cells, and hu8E5-2I-28Z-IFN T cells against subcutaneously transplanted tumors in a gastric cancer PDX model. Gastric cancer PDX tumors measuring approximately 2 × 2 × 2 mm were inoculated subcutaneously into the right armpit of 6-8 week-old female NOD / SCID mice. The day of tumor cell inoculation was recorded as D0. On D15, the NOD-SCID mice were randomly divided into three groups, each with 7 mice, into the untransfected T cell group, the hu8E5-28Z T cell group, and the hu8E5-2I-28Z-IFN T cell group. The tumor volume was 30 mm. 3 If the patient had a cyclophosphamide infection, 100 mg / kg of cyclophosphamide was administered intraperitoneally, followed by 1.0 × 10 7 CAR-T cells (hu8E5-28Z T cells or hu8E5-2I-28Z-IFN T cells) were injected via the tail vein, and a non-transfected T cell group (Mock group) was used as a control group. The growth of gastric cancer PDX subcutaneously transplanted tumors was observed and measured. The results are shown in Figure 17B, and the tumor of one mouse out of seven mice in the hu8E5-2I-28Z-IFN treatment group completely disappeared. Using the PDX model, the in vivo survival status of CAR-T cells was measured. Peripheral blood was taken from the mouse saphenous vein on days 5, 7, and 10 after CAR-T cell injection, respectively, to detect the in vivo survival status of CAR-T cells (blank T cells (Mock), hu8E5-28Z T cells, or hu8E5-2I-28Z-IFN T cells). The results were as shown in Figure 17C, and the number of surviving T cells in the hu8E5-2I-28Z-IFN T cell treatment group was significantly higher than that in the hu8E5-28Z -28Z T cell group.
[0281] Example 15. Construction of CAR-NK cells Using PRRLSIN-cPPT.EF-1α as a vector, lentiviral plasmids expressing chimeric antigen receptors for humanized antibody hu8E5 were constructed, including PRRLSIN-cPPT.EF-1α-hu8E5-28BBZ and PRRLSIN-cPPT.EF-1α-hu8E5-2I-28Z, as shown in the plasmid maps in Figures 18A and 18B. The hu8E5-28BBZ sequence consists of the CD8α signal peptide (SEQ ID NO:70), hu8E5-scFV, CD8 hinge (SEQ ID NO:72), CD28 transmembrane domain (SEQ ID NO:74), intracellular segment (SEQ ID NO:76), CD137 intracellular signaling domain segment (SEQ ID NO:82), and CD3ξ (SEQ ID NO:78), and the hu8E5-2I-28Z sequence consists of the CD8α signal peptide (SEQ ID NO:70), hu8E5-2I scFV, CD8 hinge (SEQ ID NO:72), CD28 transmembrane domain (SEQ ID NO:74), CD28 intracellular signaling domain segment (SEQ ID NO:76), and CD3 intracellular segment CD3ξ (SEQ ID NO:78).
[0282] 1. Preparation of CAR-positive NK-92 cell line 1) Coating a 24-well plate with retronectin: Add 380 μl of 5 μg / ml retronectin solution (PBS) to each well and incubate at 4°C overnight. Then inoculate the cells into the retronectin-coated 24-well plate. The number of cells in each well is 5 × 10 5 and the culture volume is 500 μl. 2) Based on MOI=30, the concentrated lentivirus was added to NK92 cells, centrifuged at 32°C for 90 minutes, and transferred to a cell incubator. 3) Amplification culture: After infection, cells were cultured at 5x10^ 5 Lymphocyte cultures were passaged at a density of 100 / mL and supplemented with recombinant human IL-2 at a final concentration of 500 U / mL.
[0283] 2. Expression of chimeric antigen receptors on NK-92 cells 1) 1x10^ cells were cultured on day 7 of lentivirus-infected NK92 cells. 6 Take the cells, divide them into two equal parts and place them in a centrifuge tube. 2) The control group cells were placed in 50 μl of PE-SA antibody (diluted 1:200), incubated on ice, and resuspended to serve as a control. The detection group cells + 50 μl of biotin-Goat anti-human IgG, F, (ab')2 antibody diluted 1:50 were incubated on ice for 45 minutes, washed twice with PBS (2% NBS), and then 50 μl of PE-SA antibody (diluted 1:200) was added and incubated on ice. 3) Add 2 ml of PBS (2% NBS) to resuspend the cells, centrifuge at 4°C, discard the supernatant, add 500 μl of PBS (2% NBS) and transfer to a flow tube. The PE channel was detected by flow cytometry to determine the ratio of CAR-positive NK92 cells. The results are shown in Figure 19.
[0284] Measurement of cytotoxicity: Target cells: 10^4 AGS, AGS-A2, BGC-823, BGC-823-A2 cells were inoculated into a 96-well plate, respectively, and effector cells: NK-92 and CAR NK-92 cells were placed based on the effector:target ratio of 6:1, 3:1, and 1.5:1, and five duplicate wells were set up for each group, and the average value of the five duplicate wells was taken. The detection time was the fourth hour. Here, the experimental groups and control groups are as follows: each experimental group: each target cell + the effector cell, control group 1: maximum release of LDH of target cells, control group 2: spontaneous release of LDH of target cells, control group 3: spontaneous release of LDH of effector cells.
[0285] Detection method: CytoTox 96 non-radioactive cytotoxicity detection kit (Promega) was used. For details, refer to the manual of the CytoTox 96 non-radioactive cytotoxicity detection kit. Cytotoxicity calculation formula: TIFF0007587921000009.tif18170
[0286] The results are shown in Figures 20 and 21, where hu8E5-21-28Z is hu8E5-2I-28Z CAR-NK92 cells and hu8E5-28BBZ is hu8E5-28BBZ CAR-NK92 cells. The results showed that hu8E5 CAR-NK92 cells had significant in vitro cell-killing activity against cells overexpressing CLDN18A2 and showed little killing activity against cells that were negative for CLDN18A2.
[0287] TIFF0007587921000010.tif241170TIFF0007587921000011.tif240170TIFF0007587921000012.tif240170TIFF0007587921000013.tif240170TIFF0007587921000014.tif241170TIFF0007587921000015.tif241170TIFF0007587921000016.tif241170TIFF0007587921000017.tif246170TIFF0007587921000018.tif241170TIFF0007587921000019.tif246170TIFF0007587921000020.tif247170TIFF0007587921000021.tif247170TIFF0007587921000022.tif241170TIFF0007587921000023.tif247170TIFF0007587921000024.tif247170TIFF0007587921000025.tif245170TIFF0007587921000026.tif244170TIFF0007587921000027.tif241170TIFF0007587921000028.tif241170TIFF0007587921000029.tif244170TIFF0007587921000030.tif247170TIFF0007587921000031.tif244170TIFF0007587921000032.tif245170TIFF0007587921000033.tif245170TIFF0007587921000034.tif242170TIFF0007587921000035.tif244170TIFF0007587921000036.tif245170TIFF0007587921000037.tif249170
Claims
1. An antibody that specifically binds to claudin 18A2, comprising heavy chain CDRs and light chain CDRs; The CDR1, CDR2 and CDR3 regions of the heavy chain variable region of the antibody are SEQ ID NO: 31, SEQ ID NO: 32, and SEQ ID NO: 33, and the CDR1, CDR2 and CDR3 regions of the light chain variable region of the antibody are SEQ ID NO: 34, SEQ ID NO: 35, and SEQ ID NO: 36; or The CDR1, CDR2 and CDR3 regions of the heavy chain variable region of the antibody are SEQ ID NO: 49, SEQ ID NO: 50, and SEQ ID NO: 51, and the CDR1, CDR2 and CDR3 regions of the light chain variable region of the antibody are SEQ ID NO: 52, SEQ ID NO: 53, and SEQ ID NO: 54; or The CDR1, CDR2 and CDR3 regions of the heavy chain variable region of the antibody are SEQ ID NO: 31, SEQ ID NO: 83, and SEQ ID NO: 33, and the CDR1, CDR2 and CDR3 regions of the light chain variable region of the antibody are SEQ ID NO: 34, SEQ ID NO: 35, and SEQ ID NO: 36; or The CDR1, CDR2 and CDR3 regions of the heavy chain variable region of the antibody are SEQ ID NO: 31, SEQ ID NO: 84, and SEQ ID NO: 33, and the CDR1, CDR2 and CDR3 regions of the light chain variable region of the antibody are SEQ ID NO: 34, SEQ ID NO: 35, and SEQ ID NO: 36; or The CDR1, CDR2 and CDR3 regions of the heavy chain variable region of the antibody are SEQ ID NO: 49, SEQ ID NO: 85, and SEQ ID NO: 51, and the CDR1, CDR2 and CDR3 regions of the light chain variable region of the antibody are SEQ ID NO: 52, SEQ ID NO: 53, and SEQ ID NO: 54; Or, The antibody is An antibody having a heavy chain variable region as shown in SEQ ID NO:3 and a light chain variable region as shown in SEQ ID NO:1; An antibody having a heavy chain variable region as set forth in SEQ ID NO: 15 and a light chain variable region as set forth in SEQ ID NO: 13; An antibody having a heavy chain variable region as set forth in SEQ ID NO: 17 and a light chain variable region as set forth in SEQ ID NO: 1; An antibody having a heavy chain variable region as set forth in SEQ ID NO: 19 and a light chain variable region as set forth in SEQ ID NO: 1; An antibody having a heavy chain variable region as set forth in SEQ ID NO: 23 and a light chain variable region as set forth in SEQ ID NO: 21; An antibody having a heavy chain variable region as set forth in SEQ ID NO: 27 and a light chain variable region as set forth in SEQ ID NO: 25; or An antibody having a heavy chain variable region as set forth in SEQ ID NO:29 and a light chain variable region as set forth in SEQ ID NO:
25.
2. The antibody of claim 1, wherein the antibody is a humanized antibody, a chimeric antibody or a fully humanized antibody, or the antibody is a monoclonal antibody, or the antibody is a single chain antibody or a domain antibody.
3. The antibody is An antibody having a heavy chain variable region as set forth in SEQ ID NO: 27 and a light chain variable region as set forth in SEQ ID NO: 25; An antibody having a heavy chain variable region as set forth in SEQ ID NO: 23 and a light chain variable region as set forth in SEQ ID NO: 21; or a humanized antibody selected from the group consisting of an antibody having a heavy chain variable region as set forth in SEQ ID NO: 29 and a light chain variable region as set forth in SEQ ID NO: 25; Or, the antibody is (a) an antibody having a heavy chain as set forth in SEQ ID NO:63 and a light chain as set forth in SEQ ID NO:65; (b) an antibody having a light chain as set forth in SEQ ID NO: 61 and a heavy chain as set forth in SEQ ID NO: 59; (c) the antibody of claim 2, selected from the group consisting of an antibody having a heavy chain as set forth in SEQ ID NO:67 and a light chain as set forth in SEQ ID NO:
65.
4. A nucleic acid encoding the antibody according to any one of claims 1 to 3, or an expression vector comprising said nucleic acid, or A host cell comprising the expression vector or having the nucleic acid integrated into its genome.
5. For producing a targeted drug, an antibody-drug conjugate or a multifunctional antibody that specifically targets tumor cells expressing claudin 18A2, or For the manufacture of a reagent for diagnosing tumors expressing claudin 18A2, or Use of an antibody according to any one of claims 1 to 3 for producing chimeric antigen receptor-modified immune cells.
6. The use according to claim 5, wherein the tumor expressing claudin 18A2 includes gastric cancer, pancreatic cancer, esophageal cancer, and lung cancer.
7. A chimeric antigen receptor comprising the antibody according to any one of claims 1 to 3, the chimeric antigen receptor comprising the sequentially linked components: the antibody according to any one of claims 1 to 3, a transmembrane domain, and an intracellular signal domain.
8. The transmembrane domain comprises a transmembrane domain of CD8 or CD28, and / or the intracellular signal domain is selected from the intracellular signal domain sequences of CD3ζ, CD28, CD137, or a combination thereof; or the transmembrane region comprises the amino acid sequence of SEQ ID NO: 73 or 79, and / or the intracellular signal region comprises the amino acid sequence of SEQ ID NO: 77, 75, 81, or a combination thereof; or The intracellular signal region comprises the amino acid sequence of SEQ ID NO: 81 and 77; or SEQ ID NO: 75 and 77; or SEQ ID NO: 75, 81 and 77; or 8. The chimeric antigen receptor of claim 7, wherein the chimeric antigen receptor comprises an amino acid sequence encoded by a nucleic acid sequence from position 64 to 1482 in SEQ ID NO: 90 or 91.
9. A nucleic acid encoding the chimeric antigen receptor according to claim 7 or 8, or an expression vector comprising said nucleic acid, or a virus comprising said vector.
10. Use of the chimeric antigen receptor of claim 7 or 8, the nucleic acid, the expression vector, or the virus of claim 9 for producing chimeric antigen receptor-modified immune cells that target tumor cells expressing claudin 18A2.
11. A chimeric antigen receptor-modified immune cell, Transduced with a nucleic acid, expression vector or virus according to claim 9, or A chimeric antigen receptor-modified immune cell, which expresses the chimeric antigen receptor according to claim 7 or 8 on its surface.
12. The chimeric antigen receptor-modified immune cell of claim 11, wherein the immune cell is a T lymphocyte, a NK cell, or a NKT lymphocyte.
13. 13. Use of the chimeric antigen receptor-modified immune cell of claim 11 or 12 for the manufacture of a drug for inhibiting a tumor, wherein the tumor is a tumor expressing claudin 18A2.
14. 1. A multifunctional immunoconjugate comprising: An antibody according to any one of claims 1 to 3 and a molecule that targets a tumor surface marker bound thereto; or An antibody according to any one of claims 1 to 3 and a tumor-inhibiting molecule bound thereto; or An antibody according to any one of claims 1 to 3 and a molecule that targets a surface marker of an immune cell bound thereto, wherein the molecule that targets a surface marker of an immune cell is an antibody that binds to a T cell surface marker, which forms a bifunctional antibody that engages T cells with the antibody according to any one of claims 1 to 3; or A multifunctional immunoconjugate comprising an antibody according to any one of claims 1 to 3 and a detectable label attached thereto.
15. A nucleic acid encoding the multifunctional immunoconjugate of claim 14.
16. For the manufacture of antitumor drugs, or For the manufacture of a reagent for diagnosing tumors expressing claudin 18A2, or 15. Use of the multifunctional immunoconjugate of claim 14 for producing chimeric antigen receptor modified immune cells.
17. 15. A pharmaceutical composition comprising an antibody according to any one of claims 1 to 3 or a nucleic acid encoding said antibody, or an immunoconjugate according to claim 14 or a nucleic acid encoding said conjugate, or a chimeric antigen receptor according to claim 7 or 8 or a nucleic acid encoding said chimeric antigen receptor, or a chimeric antigen receptor-modified immune cell according to claim 11 or 12.
18. A container and the pharmaceutical composition of claim 17 in the container; or 1. A kit comprising a container and, in the container, an antibody according to any one of claims 1 to 3 or a nucleic acid encoding said antibody, or an immunoconjugate according to claim 14 or a nucleic acid encoding said conjugate, or a chimeric antigen receptor according to claim 7 or 8 or a nucleic acid encoding said chimeric antigen receptor, or a chimeric antigen receptor-modified immune cell according to claim 11 or 12.
19. An antigen-binding unit comprising a light chain CDR and a heavy chain CDR, which specifically binds to a claudin 18A2 peptide and does not significantly bind to a claudin 18A1 peptide, The antigen-binding unit is a monoclonal antibody, a humanized antibody, a chimeric antibody, a multivalent antibody, a scFv, an Fv, a Fab or a (Fab)2; and the light chain CDRs comprise LCDR1, LCDR2 and LCDR3, and the heavy chain CDRs comprise HCDR1, HCDR2 and HCDR3; Where: The HCDR1, HCDR2 and HCDR3 of the antigen binding unit are SEQ ID NO: 31, SEQ ID NO: 32, and SEQ ID NO: 33, and the LCDR1, LCDR2 and LCDR3 of the antigen binding unit are SEQ ID NO: 34, SEQ ID NO: 35, and SEQ ID NO: 36; or The HCDR1, HCDR2 and HCDR3 of the antigen binding unit are SEQ ID NO: 49, SEQ ID NO: 50, and SEQ ID NO: 51, and the LCDR1, LCDR2 and LCDR3 of the antigen binding unit are SEQ ID NO: 52, SEQ ID NO: 53, and SEQ ID NO: 54; or The HCDR1, HCDR2 and HCDR3 of the antigen binding unit are SEQ ID NO: 31, SEQ ID NO: 83, and SEQ ID NO: 33, and the LCDR1, LCDR2 and LCDR3 of the antigen binding unit are SEQ ID NO: 34, SEQ ID NO: 35, and SEQ ID NO: 36; or The HCDR1, HCDR2 and HCDR3 of the antigen binding unit are SEQ ID NO: 31, SEQ ID NO: 84, and SEQ ID NO: 33, and the LCDR1, LCDR2 and LCDR3 of the antigen binding unit are SEQ ID NO: 34, SEQ ID NO: 35, and SEQ ID NO: 36; or The HCDR1, HCDR2 and HCDR3 of the antigen binding unit are SEQ ID NO: 49, SEQ ID NO: 85, and SEQ ID NO: 51, and the LCDR1, LCDR2 and LCDR3 of the antigen binding unit are SEQ ID NO: 52, SEQ ID NO: 53, and SEQ ID NO: 54; Antigen-binding unit.
20. A chimeric antigen receptor comprising an extracellular antigen binding unit, a transmembrane domain, and an intracellular domain, 20. The chimeric antigen receptor, wherein the extracellular antigen binding unit comprises the antigen binding unit of claim 19.
21. 21. A composition comprising the antigen binding unit of claim 19 or the chimeric antigen receptor of claim 20.
22. 22. The composition of claim 21, further comprising a type I interferon.
23. 21. An isolated nucleic acid encoding an antigen binding unit according to claim 19 or a chimeric antigen receptor according to claim 20.
24. 24. The isolated nucleic acid of claim 23, further encoding a type I interferon.
25. 21. A vector comprising a nucleic acid encoding the antigen binding unit of claim 19 or the chimeric antigen receptor of claim 20.
26. 26. The vector of claim 25, further comprising a nucleic acid encoding a type I interferon.
27. 21. A host cell expressing the antigen binding unit of claim 19 or the chimeric antigen receptor of claim 20.
28. 28. The host cell of claim 27, further expressing a type I interferon.
29. 21. A host cell comprising a nucleic acid encoding the antigen binding unit of claim 19 or the chimeric antigen receptor of claim 20.
30. 30. The host cell of claim 29, further comprising a nucleic acid encoding a type I interferon.
31. The host cell of claim 30, comprising a nucleic acid sequence of SEQ ID NO: 90 or 91 or a nucleic acid sequence comprising positions 64 to 1482 thereof.
32. The host cell is an immune response cell; or The host cell is a T cell, a natural killer cell, a cytotoxic T lymphocyte cell, a natural killer T cell, a DNT cell, and / or a regulatory T cell; or The host cell is an NK92 cell; or The host cell has cytotoxicity against a cell comprising a claudin 18A2 peptide, the claudin 18A2 peptide comprising the amino acid sequence of SEQ ID NO: 55; or The host cell of any one of claims 27 to 31, wherein the host cell does not contain a claudin 18A2 peptide and does not have significant cytotoxicity against a cell containing a claudin 18A1 peptide, the claudin 18A1 peptide comprising the amino acid sequence of SEQ ID NO: 57, and the claudin 18A2 peptide comprising the amino acid sequence of SEQ ID NO:
55.
33. 33. A method of producing an antigen binding unit according to claim 19 or a chimeric antigen receptor according to claim 20 or a composition according to claim 21, comprising culturing a host cell according to any one of claims 27 to 32 under suitable conditions and obtaining an expression product of said host cell.
34. Use of the antigen binding unit of claim 19, the chimeric antigen receptor of claim 20, the composition of claim 21, or the host cell of any one of claims 27 to 32 in the manufacture of a medicament for inducing death of a cell containing the claudin 18A2 peptide.
35. The cell is contacted with the antigen binding unit, the chimeric antigen receptor, the composition or a host cell in vitro; or The cell is contacted with the antigen binding unit, the chimeric antigen receptor, the composition or a host cell in vivo; or the cell is a cancer cell; or the cell is a solid tumor cell; or 35. The use of claim 34, wherein the cells are selected from the group consisting of gastric cancer cells, esophageal cancer cells, intestinal cancer cells, pancreatic cancer cells, nephroblastoma cells, lung cancer cells, ovarian cancer cells, colon cancer cells, rectal cancer cells, liver cancer cells, head and neck cancer cells, chronic myeloid leukemia cells and gallbladder cancer cells.
36. 36. Use of an antigen binding unit according to claim 19, a chimeric antigen receptor according to claim 20, a composition according to claim 21, a vector according to claim 25 or 26 and / or a host cell according to any one of claims 27 to 32 in the manufacture of a medicament for treating a tumour in an individual.
37. the tumor is a solid tumor; or The tumor is gastric cancer, esophageal cancer, intestinal cancer, pancreatic cancer, nephroblastoma, lung cancer, ovarian cancer, colon cancer, rectal cancer, liver cancer, head and neck cancer, chronic myeloid leukemia or gallbladder cancer; or the medicament further comprises an additional therapeutic agent; The use of claim 36, wherein the additional therapeutic agent is at least one selected from the group consisting of epirubicin, oxaliplatin, and 5-fluorouracil.
Citation Information
Patent Citations
Monoclonal antibodies against claudin-18 for treatment of cancer
CN101312989A
Antibodies against claudin 18.2 useful in cancer diagnosis
CN104321345A
Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1
Immunologic effector cell of targeted CLD18a2, and preparation method and use thereof
WO2016008405A1
